[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 235
1. Mizobe T, Tsukada J, Higashi T, Iwashige A, Ota T, Kawano I, Kubota A, Matsuura A, Morimoto H, Ogawa R, Toda Y, Tanaka Y: [Angioimmunoblastic T-cell lymphoma accompanied by pure red cell aplasia]. Rinsho Ketsueki; 2005 Mar;46(3):211-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic T-cell lymphoma accompanied by pure red cell aplasia].
  • A 71-year-old woman was admitted in December 2002 because of lymphadenopathy, hepatosplenomegaly and pleural effusion.
  • Bone marrow aspiration showed an almost total absence of erythroblasts and no pathological cell proliferation.
  • The diagnosis of angioimmunoblastic T-cell lymphoma (AILT) was made based on the lymph node histological findings.
  • After combination chemotherapy (THP-COP), remission was achieved in both the pure red cell aplasia (PRCA) and AILT.
  • Remission was also accompanied by normalization of the Coombs tests, suggesting that autoimmune mechanisms in AILT may contribute to the development of PRCA.
  • [MeSH-major] Immunoblastic Lymphadenopathy / complications. Red-Cell Aplasia, Pure / etiology

  • Genetic Alliance. consumer health - Pure red cell aplasia.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447717.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VEP-THP protocol
  • [Number-of-references] 10
  •  go-up   go-down


2. Rodig SJ, Shahsafaei A, Li B, Mackay CR, Dorfman DM: BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders. Hum Pathol; 2005 Oct;36(10):1113-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders.
  • B cell-activating factor receptor (BAFF-R) is one of three known receptors for BAFF, a critical regulator of B- and T-cell function.
  • In mice, BAFF-R is required for B-cell maturation and survival, and in mice and humans, the overproduction of BAFF is associated with autoimmune disease.
  • We sought to determine the normal pattern of BAFF-R expression at specific stages of B- and T-cell development and whether this pattern of expression corresponds with related B- and T-cell neoplasms.
  • In reactive lymphoid tissues, BAFF-R is expressed by B cells colonizing the mantle zones, by a subset of cells within germinal centers, and rare cells in the interfollicular T-cell zone.
  • Seventy-seven (78%) of 116 cases of B-cell lymphoproliferative disorders were BAFF-R-positive by immunohistochemical and/or flow cytometric immunophenotypic analysis, including most cases of mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, hairy cell leukemia, and diffuse large B-cell lymphoma.
  • In contrast, cases of precursor B lymphoblastic lymphoma, Burkitt lymphoma, and nodular lymphocyte-predominant Hodgkin lymphoma exhibit weak to negative staining for BAFF-R.
  • All cases of classical Hodgkin lymphoma and T-cell lymphomas were BAFF-R-negative, including all cases of anaplastic large cell lymphoma, adult T-cell leukemia/lymphoma, angioimmunoblastic T-cell lymphoma, and peripheral T-cell lymphoma, unspecified.
  • These findings highlight BAFF-R as a marker of both normal and neoplastic B cells and raise the possibility that BAFF-R expression is necessary for the survival of a subset of neoplastic B lymphocytes analogous to its known role in promoting normal B-cell maturation and survival.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16226112.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Interleukin-4
  •  go-up   go-down


3. Murakami YI, Yatabe Y, Sakaguchi T, Sasaki E, Yamashita Y, Morito N, Yoh K, Fujioka Y, Matsuno F, Hata H, Mitsuya H, Imagawa S, Suzuki A, Esumi H, Sakai M, Takahashi S, Mori N: c-Maf expression in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol; 2007 Nov;31(11):1695-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] c-Maf expression in angioimmunoblastic T-cell lymphoma.
  • We previously examined c-Maf expression in various T-cell lymphomas by reverse-transcription polymerase chain reaction and found extremely elevated c-Maf levels in angioimmunoblastic T-cell lymphoma (AILT).
  • In this study, we examined T-cell lymphomas for c-Maf and cyclin expression immunohistochemically.
  • Of 93 cases of T-cell lymphomas we investigated in the current study, c-Maf expression was seen in 23 out of 31 cases of AILT, 3 out of 11 of adult T-cell leukemia/lymphoma, 4 out of 19 of peripheral T-cell lymphoma, unspecified [PTCL(U)], and 0 out of 11 cases of mycosis fungoides, 0 out of 11 of anaplastic large cell lymphoma, and 1 out of 10 of extranodal NK/T-cell lymphoma, nasal type.
  • Double immunostaining in AILT revealed that the majority of c-Maf-positive cells were also positive for CD43 (MT1), CD45RO (UCHL-1), and CD4 but were negative for CD20 (L26).
  • Additionally, cyclins D1 and D2, which stimulate cell cycle progression, were overexpressed in a large number of the c-Maf-positive AILT samples.
  • Quantitative reverse-transcription polymerase chain reaction analysis also showed that c-Maf was overexpressed in 8/31 cases of AILT, 0/19 cases of PTCL(U), 0/11 cases of anaplastic large cell lymphoma, 0/10 cases of extranodal NK/T-cell lymphoma, nasal type, and 2/8 cases of multiple myeloma, presenting significant difference between AILT and PTCL(U) (P=0.016, chi test).
  • These findings strongly suggest that CD4-positive neoplastic T cells in AILT show c-Maf expression and provide new insight into the pathogenesis of AILT suggesting c-Maf to be a useful diagnostic marker for AILT.
  • [MeSH-major] Biomarkers, Tumor / analysis. Immunoblastic Lymphadenopathy / metabolism. Lymphoma, T-Cell / chemistry. Proto-Oncogene Proteins c-maf / analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18059226.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD4; 0 / Antigens, CD43; 0 / Biomarkers, Tumor; 0 / CCND2 protein, human; 0 / Cyclin D; 0 / Cyclin D2; 0 / Cyclins; 0 / MAF protein, human; 0 / Proto-Oncogene Proteins c-maf; 0 / RNA, Messenger; 0 / UN1 sialoglycoprotein, human; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


Advertisement
4. Zhang LX, Ye J, Lu TH, Jiang GN, Xiao W, Zhu XJ, Chen YB, Xing TJ, Wu ZD, Huang JX: [Immunophenotype analysis on neoplastic cells in bone marrow and peripheral blood of angioimmunoblastic T-cell lymphoma]. Zhonghua Bing Li Xue Za Zhi; 2009 Aug;38(8):552-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunophenotype analysis on neoplastic cells in bone marrow and peripheral blood of angioimmunoblastic T-cell lymphoma].
  • [MeSH-major] Bone Marrow Cells / pathology. Immunoblastic Lymphadenopathy / pathology. Immunophenotyping / methods. Lymphoma, T-Cell / pathology

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021969.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD28; 0 / Antigens, CD4; 0 / Antigens, CD95; 0 / Receptors, Complement 3d; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


5. Bonzheim I, Geissinger E, Tinguely M, Roth S, Grieb T, Reimer P, Wilhelm M, Rosenwald A, Müller-Hermelink HK, Rüdiger T: Evaluation of FoxP3 expression in peripheral T-cell lymphoma. Am J Clin Pathol; 2008 Oct;130(4):613-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of FoxP3 expression in peripheral T-cell lymphoma.
  • Peripheral T-cell lymphomas (PTCLs) are biologically heterogeneous and have not been successfully correlated with specific T-cell subsets.
  • We investigated PTCL, not otherwise specified (NOS), angioimmunoblastic T-cell lymphoma (AILT), and anaplastic large cell lymphoma (ALCL) cases for FoxP3 expression to determine a potential derivation from regulatory T (Treg) cells.
  • One PTCL-NOS case strongly expressed FoxP3 in the neoplastic T cells and showed unusual histomorphologic features with a dense infiltration of the lymph node by immunoblastic T cells and almost no reactive background infiltrate.
  • The patient died shortly after diagnosis, suggesting that biologic properties of Treg cells may have contributed to the rapidly fatal clinical course.
  • All remaining PTCL-NOS and AILT cases showed FoxP3 positivity only in the reactive infiltrate.
  • FoxP3+ PTCL-NOS presumably derived from bona fide Treg cells occurs but seems rare in the Western population.
  • [MeSH-major] Forkhead Transcription Factors / biosynthesis. Lymphoma, T-Cell, Peripheral / immunology. Lymphoma, T-Cell, Peripheral / metabolism. T-Lymphocyte Subsets / metabolism. T-Lymphocytes, Regulatory / metabolism

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Zurich Open Access Repository and Archive. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794055.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


6. Sellier S, Levesque H, Courville P, Joly P: [Cyclophosphamide-induced neutrophilic disease in a patient with angioimmunoblastic lymphadenopathy and myelodysplastic syndrome]. Ann Dermatol Venereol; 2006 May;133(5 Pt 1):459-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cyclophosphamide-induced neutrophilic disease in a patient with angioimmunoblastic lymphadenopathy and myelodysplastic syndrome].
  • [Transliterated title] Dermatose neutrophilique, au décours d'une lymphadénopathie angio-immunoblastique, avec dysmyélopoïèse induite par le cyclophosphamide.
  • BACKGROUND: Cutaneous involvement in patients with angioimmunoblastic lymphadenopathy is often poorly specific for maculopapular eruptions.
  • We report an atypical case of neutrophilic disorder associating subcorneal pustules and hypodermal nodules in a male patient with angioimmunoblastic lymphadenopathy.
  • CASE REPORT: A 62 year-old man with angioimmunoblastic lymphadenopathy was treated with oral prednisone (15 mg/day) and cyclophosphamide.
  • Biopsy of these lesions showed an infiltration of neutrophil polymorphonuclears in the median and superficial dermis with a subcorneal pustule and nodular infiltration of neutrophil polymorphonuclears in the deep dermis and hypodermis respectively.
  • DISCUSSION: This atypical case of neutrophilic disorder associating acute subcorneal pustules and deep dermal-hypodermal nodules seems to correspond to a unique type of neutrophilic disorder that differs from those previously reported in the literature.
  • Neutrophilic disorders have been reported only rarely in patients with angioimmunoblastic lymphadenopathy.
  • [MeSH-major] Cyclophosphamide / adverse effects. Immunoblastic Lymphadenopathy / drug therapy. Immunosuppressive Agents / adverse effects. Neutrophil Infiltration. Skin Diseases, Vesiculobullous / immunology

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16760835.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


7. Lee Y, Lee KW, Kim JH, Bang SM, Lee JS, Park BB, Kim WS, Suh C, Kang JH, Ryoo BY, Lee JH, Shin DB: Epstein-Barr virus-positivity in tumor has no correlation with the clinical outcomes of patients with angioimmunoblastic T-cell lymphoma. Korean J Intern Med; 2008 Mar;23(1):30-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-positivity in tumor has no correlation with the clinical outcomes of patients with angioimmunoblastic T-cell lymphoma.
  • BACKGROUND/AIMS: Epstein-Barr virus (EBV) is involved in the pathogenesis of angioimmunoblastic T-cell lymphoma (AILT), but its precise role and prognostic impact are not clear.
  • This study aimed to evaluate the incidence of EBV-postitivity in the tumor and bone marrow (BM) samples from AILT patients, and their correlations with the clinical variables and patient survival.
  • METHODS: Seventy AILT cases were identified over a period of 8 years.
  • In 13 (48%) patients, gross tumor involvement was recognized by hematoxylin-eosin staining at the time of diagnosis.
  • CONCLUSIONS: EBV-positivity of tumor had no impact on the prognosis of AILT patients.
  • [MeSH-major] Herpesvirus 4, Human / isolation & purification. Immunoblastic Lymphadenopathy / virology. Lymphoma, T-Cell / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Feb;156(2):661-9 [10666395.001]
  • [Cites] Am J Clin Pathol. 2007 Jun;127(6):860-8 [17509983.001]
  • [Cites] Am J Clin Pathol. 2000 Aug;114(2):236-47 [10941339.001]
  • [Cites] Am J Clin Pathol. 2002 Mar;117(3):368-79 [11888076.001]
  • [Cites] Leuk Lymphoma. 2002 Apr;43(4):805-11 [12153168.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):12-20 [12455048.001]
  • [Cites] Lancet Infect Dis. 2003 Mar;3(3):131-40 [12614729.001]
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1328-37 [15044644.001]
  • [Cites] J Korean Med Sci. 2004 Apr;19(2):229-33 [15082896.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1467-75 [15367405.001]
  • [Cites] Int J Cancer. 1976 Feb 15;17(2):177-81 [175027.001]
  • [Cites] Blood. 1991 Feb 15;77(4):799-808 [1847084.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1789-95 [1373088.001]
  • [Cites] Blood. 1992 Jul 15;80(2):484-91 [1320954.001]
  • [Cites] Blood. 1992 Oct 1;80(7):1804-12 [1327284.001]
  • [Cites] Histopathology. 1993 Feb;22(2):145-9 [8384155.001]
  • [Cites] Ann Oncol. 1995 Sep;6(7):659-64 [8664186.001]
  • [Cites] Haematologica. 2005 Aug;90(8):1063-9 [16079105.001]
  • [Cites] Haematologica. 2005 Sep;90(9):1192-6 [16154842.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:260-6 [16304390.001]
  • [Cites] J Mol Diagn. 2006 Sep;8(4):466-75; quiz 527 [16931587.001]
  • [Cites] Leuk Lymphoma. 2007 Apr;48(4):716-22 [17454629.001]
  • [Cites] N Engl J Med. 2000 Aug 17;343(7):481-92 [10944566.001]
  • (PMID = 18363277.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC2686953
  •  go-up   go-down


8. Jones D: Functional classification of peripheral T-cell lymphomas as an approach to improve outcome prediction and therapy selection. Semin Hematol; 2010 Apr;47 Suppl 1:S1-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional classification of peripheral T-cell lymphomas as an approach to improve outcome prediction and therapy selection.
  • Many types of peripheral T-cell lymphoma (PTCL) are currently classified by the World Health Organization (WHO) based on their predominant site of organ involvement (eg, intestinal or cutaneous types).
  • However, this approach and traditional staging scores such as the IPI can provide limited prognostic information, especially in those PTCL types where morbidity and mortality are primarily related to immune dysregulation and cytokine syndromes driven by the lymphoma cells.
  • These "immune participatory" PTCLs (including, commonly, angioimmunoblastic T-cell lymphoma and many extranodal types) can therefore have poor outcomes even at low tumor burdens.
  • For these reasons, a classification that includes functional profiling of the lymphoma cells may add valuable prognostic information.
  • Such data, including cytokine expression patterns and T-cell receptor signaling pathway activation status, whether normal or abnormal, need to be considered in future classification systems, especially when incorpating targeted therapy.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / classification
  • [MeSH-minor] Cell Differentiation. Humans. Leukemia-Lymphoma, Adult T-Cell / classification. Leukemia-Lymphoma, Adult T-Cell / pathology. Lymphoma, Large-Cell, Anaplastic / classification. Lymphoma, Large-Cell, Anaplastic / pathology. Lymphoma, T-Cell / classification. Lymphoma, T-Cell / pathology. Lymphoproliferative Disorders / classification. Lymphoproliferative Disorders / pathology. Prognosis. Receptors, Antigen, T-Cell / immunology. T-Lymphocytes / pathology. World Health Organization

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20359579.001).
  • [ISSN] 1532-8686
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell
  • [Number-of-references] 13
  •  go-up   go-down


9. Gottardi M, Danesin C, Canal F, Dei Tos AP, Stefani PM, Calistri E, Salvadori U, Gherlinzoni F: Complete remission induced by thalidomide in a case of angioimmunoblastic T-cell lymphoma refractory to autologous stem cell transplantation. Leuk Lymphoma; 2008 Sep;49(9):1836-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission induced by thalidomide in a case of angioimmunoblastic T-cell lymphoma refractory to autologous stem cell transplantation.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, T-Cell, Peripheral / drug therapy. Thalidomide / therapeutic use
  • [MeSH-minor] Humans. Immunoblastic Lymphadenopathy. Male. Middle Aged. Remission Induction / methods. Salvage Therapy / methods. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18661402.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


10. Niitsu N, Okamoto M, Nakamine H, Aoki S, Motomura S, Hirano M: Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas. Hematol Oncol; 2008 Sep;26(3):152-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas.
  • We studied the clinico-pathologic features and treatment outcome of patients with peripheral T-cell lymphoma (PTCL).
  • This study included 215 patients with T/natural killer (NK)-cell lymphoma, including 59 with PTCL-unspecified (PTCL-U), 42 with angioimmunoblastic T-cell lymphoma (AILT) and 20 with anaplastic large-cell lymphoma (ALCL).
  • Most of the analyses were performed on patients with AILD, ALCL and PTCL-U.
  • The patients with AILT and PTCL-U tended to be older than those with ALCL.
  • Stage III/IV disease was seen in 90.5% of the AILT cases, 55% of the ALCL cases and 67.8% of the PTCL-U cases.
  • In addition, 61.9% of the AILT cases had an international prognostic index (IPI) of H-I or H risk.
  • The 5-year progression-free survival (PFS) and overall survival (OS) rates were 72.2 and 76.1% among the ALCL cases, 40.7 and 42.2% among the PTCL-U cases and 31.2 and 49.3% among the AILT cases, respectively.
  • The 5-year PFS and OS rates among patients who received CHOP therapy, CyclOBEAP [cyclophosphamide (CPA), vincristine (VCR), bleomycine, etoposide, doxorubicin (DXR), prednisone (PDN)] therapy or autologous stem cell transplantation were: 22 and 25.7%, 59 and 61.7% or 33.3 and 60%, respectively.
  • PTCL-U is a heterogeneous disease with regard to histological type and pathological state.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 John Wiley & Sons, Ltd.
  • (PMID = 18395866.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


11. Yoon GS, Choi YK, Bak H, Kim BJ, Kim MN, Choi J, Rheu HM, Huh J, Choi JH, Chang SE: Angioimmunoblastic T cell lymphomas: frequent cutaneous skin lesions and absence of human herpes viruses. Ann Dermatol; 2009 Feb;21(1):1-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T cell lymphomas: frequent cutaneous skin lesions and absence of human herpes viruses.
  • BACKGROUND: Angioimmunoblastic T-cell lymphoma (AITL) is a complex lymphoproliferative disorder and often mimics a viral infection with frequent skin involvement.
  • In situ hybridization of EBV early region RNA (EBER) was performed and T cell receptor (TCR) gene rearrangement was also investigated in some cases.
  • CONCLUSION: Skin manifestation seems to be a cardinal component of AITL, be it in the context of presentation, progression or recurrent disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cutan Pathol. 2006 Sep;33 Suppl 2:6-11 [16972945.001]
  • [Cites] Br J Haematol. 2007 Jul;138(1):44-53 [17555446.001]
  • [Cites] J Am Acad Dermatol. 1979 Sep;1(3):227-32 [512072.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1789-95 [1373088.001]
  • [Cites] Arch Dermatol. 1980 Jan;116(1):41-5 [6444351.001]
  • [Cites] Cancer. 1981 Dec 1;48(11):2493-8 [7296497.001]
  • [Cites] Leuk Res. 1993 Nov;17(11):1003-11 [8231227.001]
  • [Cites] Haematologica. 1996 May-Jun;81(3):265-81 [8767534.001]
  • [Cites] J Am Acad Dermatol. 1997 Feb;36(2 Pt 2):290-5 [9039203.001]
  • [Cites] Leukemia. 1997 Jun;11(6):882-5 [9177444.001]
  • [Cites] Arch Dermatol. 2000 Jul;136(7):881-6 [10890990.001]
  • [Cites] J Cutan Pathol. 2001 Sep;28(8):432-8 [11493382.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):681-91 [12780782.001]
  • [Cites] Hematol Oncol. 2004 Dec;22(4):169-77 [16134192.001]
  • (PMID = 20548847.001).
  • [ISSN] 2005-3894
  • [Journal-full-title] Annals of dermatology
  • [ISO-abbreviation] Ann Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2883358
  • [Keywords] NOTNLM ; Angioimmunoblastic T-cell lymphoma / Epstein-Barr virus / Human herpes virus
  •  go-up   go-down


12. Geissinger E, Bonzheim I, Krenács L, Roth S, Ströbel P, Ott G, Reimer P, Wilhelm M, Müller-Hermelink HK, Rüdiger T: Identification of the tumor cells in peripheral T-cell lymphomas by combined polymerase chain reaction-based T-cell receptor beta spectrotyping and immunohistological detection with T-cell receptor beta chain variable region segment-specific antibodies. J Mol Diagn; 2005 Oct;7(4):455-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of the tumor cells in peripheral T-cell lymphomas by combined polymerase chain reaction-based T-cell receptor beta spectrotyping and immunohistological detection with T-cell receptor beta chain variable region segment-specific antibodies.
  • Most nodal peripheral T-cell lymphomas (PTCL) originate from alphabeta-T cells, and they often contain reactive T cells that may hamper immunophenotyping.
  • To specifically identify the neoplastic population in immunohistochemically stained slides, we assessed the heterogeneity of the T-cell receptor beta chain variable region (TCRVbeta).
  • The TCRVbeta segment of the tumor cells was defined in 13 of 13 PTCL not otherwise specified and 11 of 13 angioimmunoblastic T-cell lymphomas.
  • [MeSH-major] Antibodies / immunology. Lymphoma, T-Cell, Peripheral / genetics. Lymphoma, T-Cell, Peripheral / pathology. Polymerase Chain Reaction. Receptors, Antigen, T-Cell, alpha-beta / genetics. Receptors, Antigen, T-Cell, alpha-beta / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1997 Dec;183(4):432-9 [9496260.001]
  • [Cites] Blood. 2001 Jul 1;98(1):165-73 [11418476.001]
  • [Cites] Am J Pathol. 1988 Dec;133(3):549-56 [2849301.001]
  • [Cites] Histopathology. 1988 Jul;13(1):19-41 [3061921.001]
  • [Cites] Am J Clin Pathol. 1989 Feb;91(2):152-8 [2464922.001]
  • [Cites] Br J Cancer. 1988 Dec;58(6):723-9 [2852027.001]
  • [Cites] Am J Pathol. 1990 May;136(5):1093-9 [2161617.001]
  • [Cites] Hum Pathol. 1990 Nov;21(11):1117-25 [2227919.001]
  • [Cites] Cancer. 1991 May 15;67(10):2566-78 [1826629.001]
  • [Cites] Eur J Haematol. 1991 Sep;47(3):168-73 [1915799.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):661-9 [10666395.001]
  • [Cites] Blood. 2000 Jul 15;96(2):640-6 [10887129.001]
  • [Cites] Cytometry. 2000 Aug 1;40(4):336-45 [10918284.001]
  • [Cites] J Immunol. 2000 Aug 15;165(4):2020-7 [10925285.001]
  • [Cites] J Immunol Methods. 2000 Dec 1;246(1-2):131-43 [11121554.001]
  • [Cites] J Histochem Cytochem. 2001 Feb;49(2):139-45 [11156682.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1851-7 [11337383.001]
  • [Cites] Mol Diagn. 2001 Sep;6(3):169-79 [11571710.001]
  • [Cites] Curr Opin Immunol. 2002 Feb;14(1):52-65 [11790533.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] Pathol Res Pract. 2002;198(6):389-95 [12166895.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):12-20 [12455048.001]
  • [Cites] Hematol J. 2003;4(1):18-25 [12692516.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):785-94 [14608907.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):334-43 [15480768.001]
  • [Cites] Blood. 1986 Feb;67(2):474-8 [3080041.001]
  • [Cites] Blood. 1986 Sep;68(3):663-7 [2943330.001]
  • [Cites] Am J Pathol. 1987 Jul;128(1):181-201 [3111266.001]
  • [Cites] Br J Haematol. 1987 Aug;66(4):451-60 [3499166.001]
  • [Cites] Br J Haematol. 1987 Sep;67(1):19-24 [3499172.001]
  • [Cites] Cancer. 1988 May 15;61(10):2060-70 [2896068.001]
  • [Cites] Blood. 1988 Aug;72(2):413-21 [3261178.001]
  • [Cites] Nature. 1988 Aug 4;334(6181):395-402 [3043226.001]
  • [Cites] Blood. 1988 Sep;72(3):1000-6 [3046680.001]
  • [Cites] Int J Cancer. 1992 Jan 21;50(2):186-91 [1730511.001]
  • [Cites] Eur J Immunol. 1992 Feb;22(2):541-9 [1311263.001]
  • [Cites] J Pathol. 1992 Feb;166(2):109-12 [1560311.001]
  • [Cites] Acta Pathol Jpn. 1992 Feb;42(2):141-9 [1314007.001]
  • [Cites] Cancer. 1992 May 15;69(10):2571-82 [1568182.001]
  • [Cites] Hum Immunol. 1992 Sep;35(1):60-7 [1478894.001]
  • [Cites] Leuk Lymphoma. 1992 Aug;7(5-6):449-55 [1493445.001]
  • [Cites] Histopathology. 1993 Apr;22(4):303-10 [8514273.001]
  • [Cites] Acta Pathol Jpn. 1993 Jul-Aug;43(7-8):396-412 [8372685.001]
  • [Cites] Immunol Today. 1993 Aug;14(8):391-4 [8397778.001]
  • [Cites] Leukemia. 1994 Feb;8(2):295-8 [8309253.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Virchows Arch. 1994;425(1):25-32 [7921409.001]
  • [Cites] Hum Immunol. 1995 Jul;43(3):207-18 [7558938.001]
  • [Cites] Immunogenetics. 1995;42(6):451-3 [8550091.001]
  • [Cites] Immunogenetics. 1995;42(6):455-500 [8550092.001]
  • [Cites] Am J Clin Pathol. 1998 May;109(5):610-7 [9576581.001]
  • [Cites] Mod Pathol. 1998 Apr;11(4):313-23 [9578080.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):643-55 [9630171.001]
  • [Cites] J Biol Chem. 1998 Sep 11;273(37):23709-15 [9726977.001]
  • [Cites] Hum Pathol. 1999 Jan;30(1):48-53 [9923926.001]
  • [Cites] J Immunol Methods. 1999 Apr 22;224(1-2):203-8 [10357220.001]
  • [Cites] Leukemia. 1999 Jun;13(6):965-74 [10360387.001]
  • [Cites] Am J Surg Pathol. 1999 Oct;23(10):1184-200 [10524519.001]
  • [Cites] Br J Dermatol. 1995 Dec;133(6):978-82 [8547055.001]
  • [Cites] Science. 1996 Jun 21;272(5269):1755-62 [8650574.001]
  • [Cites] Science. 1996 Jul 5;273(5271):104-6 [8658175.001]
  • [Cites] Cytometry. 1996 Jun 15;26(2):148-53 [8817091.001]
  • [Cites] Auris Nasus Larynx. 1997 Apr;24(2):199-206 [9134144.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4501-13 [9192774.001]
  • [Cites] Mol Pathol. 1997 Feb;50(1):15-7 [9208808.001]
  • (PMID = 16237215.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, CD3; 0 / Receptors, Antigen, T-Cell, alpha-beta
  • [Other-IDs] NLM/ PMC1885558
  •  go-up   go-down


13. Lin O, Filippa DA, Teruya-Feldstein J: Immunohistochemical evaluation of FLI-1 in acute lymphoblastic lymphoma (ALL): a potential diagnostic pitfall. Appl Immunohistochem Mol Morphol; 2009 Oct;17(5):409-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical evaluation of FLI-1 in acute lymphoblastic lymphoma (ALL): a potential diagnostic pitfall.
  • Cases of CD45-negative acute lymphoblastic lymphoma/leukemia (ALL) immunoreactive for CD99 and Friend Leukemia Integration-1 (FLI-1) can occur and may lead to a misdiagnosis of Ewing sarcoma/peripheral neuroectodermal tumor with critical clinical treatment management implications.
  • The objective of this study was to evaluate a panel of antibodies that would allow greater diagnostic accuracy of ALL and evaluate the frequency of FLI-1 immunoreactivity in a series of ALL cases and an expanded series of T-cell lymphoma subtypes.
  • Therefore, CD43 and/or TdT should be included in the immunohistochemical evaluation of small round blue cell tumors.
  • Absence of immunoreactivity for LCA does not exclude ALL and immunoreactivity of FLI-1 is not restricted to Ewing sarcoma/peripheral neuroectodermal tumor.
  • We also report FLI-1 expression in an expanded series of 75 cases of T-cell lymphoma and found high expression in anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma.

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19349856.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FLI1 protein, human; 0 / Proto-Oncogene Protein c-fli-1
  •  go-up   go-down


14. Hatanaka K, Nakamura N, Kojima M, Ando K, Irie S, Bunno M, Nakamine H, Uekusa T: Methotrexate-associated lymphoproliferative disorders mimicking angioimmunoblastic T-cell lymphoma. Pathol Res Pract; 2010 Jan 15;206(1):9-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methotrexate-associated lymphoproliferative disorders mimicking angioimmunoblastic T-cell lymphoma.
  • Patients affected by autoimmune diseases (rheumatoid arthritis (RA), psoriasis, and dermatomyositis) treated with methotrexate (MTX) develop lymphoproliferative disorders (LPDs).
  • These cases have been reported to be diffuse large B-cell lymphoma, Hodgkin lymphoma, or polymorphous post-transplant LPDs.
  • However, angioimmunoblastic T-cell lymphoma (AITL) is extremely rare in the medical literature.
  • The affected lymph nodes showed the histological finding of AITL: polymorphous infiltrates, mainly T-cells and arborizing high endothelial venules.
  • [MeSH-major] Arthritis, Rheumatoid / drug therapy. Immunoblastic Lymphadenopathy / diagnosis. Lymphoma, T-Cell / diagnosis. Lymphoproliferative Disorders / chemically induced. Lymphoproliferative Disorders / diagnosis. Methotrexate / adverse effects
  • [MeSH-minor] Aged. Antirheumatic Agents / adverse effects. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Cell Proliferation. Diagnosis, Differential. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / immunology. Female. Herpesvirus 4, Human / immunology. Humans. Male

  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19628340.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antirheumatic Agents; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


15. Laforga JB, Gasent JM, Vaquero M: Potential misdiagnosis of angioimmunoblastic T-cell lymphoma with Hodgkin's lymphoma: a case report. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):840-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential misdiagnosis of angioimmunoblastic T-cell lymphoma with Hodgkin's lymphoma: a case report.
  • BACKGROUND: Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive neoplasm.
  • We investigated the potential utility of touch imprints evaluated in conjunction with the histology of lymph nodes in the diagnosis of AITL.
  • CASE A 58-year-old man presented with generalized lymphadenopathy, splenomegaly, and autoimmune phenomena, which complicated the diagnosis.
  • Touch imprints were obtained from the lymph node biopsy, which were valuable in making the correct diagnosis.
  • CONCLUSION: We draw attention to this neoplastic diagnosis and correlate the cytomorphologic and immunohistochemical findings with the adequate clinical setting in order to avoid misdiagnosis, primarily with Hodgkin's lymphoma and reactive hyperplasia.
  • Touch imprints are useful in the diagnosis of AITL if the broad population of proliferating cells is distinguished.
  • However, some cases display binucleated or mononucleated cells with prominent nucleoli and many eosinophils, which may induce a potential misdiagnosis with Hodgkin's lymphoma.
  • [MeSH-major] Diagnostic Errors. Hodgkin Disease / diagnosis. Immunoblastic Lymphadenopathy / diagnosis. Lymphoma, T-Cell / diagnosis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053552.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Ren YL, Hong L, Nong L, Zhang S, Li T: [Clinicopathologic, immunohistochemical and molecular analysis in 15 cases of angioimmunoblastic T-cell lymphomas]. Beijing Da Xue Xue Bao; 2008 Aug 18;40(4):352-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic, immunohistochemical and molecular analysis in 15 cases of angioimmunoblastic T-cell lymphomas].
  • OBJECTIVE: To evaluate angioimmunoblastic T-cell lymphoma(AITL) completely, we gave injdepth investigation of histopathological features, specific immunochemical markers, antigen receptor gene rearrangements and in situ hybridization for Epstein-Barr virus (EBV).
  • Polymerase chain reaction for immunoglobulin heavy chain (IgH) and T cell receptor gamma (TCRgamma) rearrangements and in situ hybridization for Epstein-Barr virus encoded RNA (EBER-1) were performed.
  • CD21 expression exihibited extrafollicular expansion of follicular dendritic cell meshworks in 11 cases (73.3%), partially with a tendency of perivascular distribution.
  • Among the four cases with large B cell proliferation, three were EBV-positive.
  • Only when we recognize such diversity, can we reasonably apply and properly evaluate immunochemical markers and molecular techniques, and thus give a correct diagnosis.
  • [MeSH-major] Gene Rearrangement, T-Lymphocyte. Immunoblastic Lymphadenopathy. Lymphoma, T-Cell, Peripheral
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Epstein-Barr Virus Infections / metabolism. Epstein-Barr Virus Infections / pathology. Female. Humans. Immunoglobulin Heavy Chains / genetics. Immunohistochemistry. Male. Middle Aged. Receptors, Antigen, T-Cell, gamma-delta / genetics. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18677379.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


17. Basu D, Bundele M: Angioimmunoblastic T-cell lymphoma obscured by concomitant florid epithelioid cell granulomatous reaction--a case report. Indian J Pathol Microbiol; 2005 Oct;48(4):500-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma obscured by concomitant florid epithelioid cell granulomatous reaction--a case report.
  • Epithelioid cell granuloma occurs in association with many neoplasms including lymphoma.
  • However they have rarely obscured the microscopic features of a lymphoma.
  • We report on a case where a florid epithelioid cell granulomatous reaction caused difficulty in interpretation and delayed the final diagnosis of a case of peripheral T cell lymphoma of the angioimmunoblastic type.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] Diagnosis, Differential. Epithelioid Cells / pathology. Granuloma / pathology. Humans. Immunoblastic Lymphadenopathy / pathology. Lymphadenitis / diagnosis. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366110.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


18. Dunleavy K: Angioimmunoblastic T-cell lymphoma (AILT): a unique clinical and pathobiological entity. Onkologie; 2008 Oct;31(10):509-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma (AILT): a unique clinical and pathobiological entity.
  • [MeSH-major] Cardiac Tamponade / diagnosis. Cardiac Tamponade / etiology. Immunoblastic Lymphadenopathy / complications. Immunoblastic Lymphadenopathy / diagnosis. Lymphoma / complications. Lymphoma / diagnosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Onkologie. 2008 Oct;31(10):546-8 [18854655.001]
  • (PMID = 18854648.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] Switzerland
  •  go-up   go-down


19. Lachenal F: [Angioimmunoblastic T-cell lymphoma]. Presse Med; 2007 Nov;36(11 Pt 2):1655-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic T-cell lymphoma].
  • [Transliterated title] Lymphomes T angio-immunoblastiques.
  • Angioimmunoblastic T-cell lymphoma most often affects the elderly.
  • Patients present with generalized lymphadenopathy and systemic symptoms; half also have hepatomegaly, splenomegaly and a rash.
  • Lymph node biopsy is needed to confirm this diagnosis.
  • Genetic analysis that reveals a monoclonal T-cell population is also relevant.
  • Autologous stem cell transplantation is proposed to the youngest.
  • [MeSH-major] Immunoblastic Lymphadenopathy. Lymphoma, T-Cell

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17587541.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 79
  •  go-up   go-down


20. Renner R, Kauer F, Treudler R, Niederwieser D, Simon JC: Eosinophilic cellulitis (Wells' syndrome) in association with angioimmunoblastic lymphadenopathy. Acta Derm Venereol; 2007;87(6):525-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eosinophilic cellulitis (Wells' syndrome) in association with angioimmunoblastic lymphadenopathy.
  • Eosinophilic cellulitis (Wells' syndrome) is an uncommon inflammatory disease with clinical polymorphism.
  • It is often associated with infectious, allergic or myeloproliferative diseases; however, the exact aetiology is unknown.
  • This report describes a rare case of eosinophilic cellulitis in association with angioimmunoblastic lymphadenopathy.
  • The typical skin findings of Wells' syndrome disappeared completely following chemotherapy and autologous stem cell transplantation.
  • [MeSH-major] Cellulitis / complications. Eosinophilia / complications. Immunoblastic Lymphadenopathy / complications. Skin Diseases / complications


21. Decouvelaere AV, Morschhauser F, Buob D, Copin MC, Dumontet C: Heterogeneity of protein kinase C beta(2) expression in lymphoid malignancies. Histopathology; 2007 Apr;50(5):561-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Protein kinase C (PKC) beta is an important regulator of lymphoid survival and its expression has been shown to be altered in lymphomas.
  • The aim was to determine the expression of PKC beta(2) in various subtypes of lymphoproliferative diseases by immunohistochemistry.
  • METHODS AND RESULTS: One hundred and forty archival samples representing various subtypes of lymphoproliferative diseases were analysed.
  • Certain subtypes, such as mantle cell, lymphocytic or follicular lymphoma, were found to express PKC beta(2) in > 90% of the samples.
  • In follicular lymphomas, the follicular lymphomatous areas were constantly labelled, whereas residual germinal centres remained negative.
  • Most angioimmunoblastic T-cell lymphomas, lymphoblastic T-cell lymphomas and marginal zone/mucosa-associated lymphoid tissue (MALT) lymphomas were labelled with anti-PKC betaII antibody, but the pattern of expression was more heterogeneous in these subtypes.
  • A minority of diffuse large B-cell lymphomas were stained and most plasma cell malignancies were negative.
  • None of the cases of Hodgkin's disease and anaplastic large cell lymphoma expressed PKC beta(2).
  • CONCLUSIONS: PKC beta(2) expression varies significantly among lymphoproliferative diseases.
  • In our series, the highest level of expression was found in mantle cell lymphomas and chronic lymphocytic lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17394491.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Isoenzymes; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / Protein Kinase C beta
  •  go-up   go-down


22. Chen W, Kesler MV, Karandikar NJ, McKenna RW, Kroft SH: Flow cytometric features of angioimmunoblastic T-cell lymphoma. Cytometry B Clin Cytom; 2006 May;70(3):142-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flow cytometric features of angioimmunoblastic T-cell lymphoma.
  • BACKGROUND: The immunophenotypic features of angioimmunoblastic T-cell lymphoma (AILT) have not been well described.
  • METHODS: We retrospectively reviewed our institutional experience with the flow cytometric features of 16 cases of AILT.
  • CD10 was expressed by the neoplastic populations in 11 of 14 cases at diagnosis; in 3 of these 11 only a subpopulation of the neoplastic cells was CD10(+).
  • CONCLUSIONS: These results indicate the potential utility of flow cytometry in the diagnosis and follow-up of AILT.
  • [MeSH-major] Flow Cytometry / methods. Immunoblastic Lymphadenopathy / pathology. Immunophenotyping / methods. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / analysis. Antigens, CD3 / analysis. Antigens, CD45 / analysis. Antigens, CD7 / analysis. Bone Marrow / pathology. Female. Follow-Up Studies. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor / genetics. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neprilysin / analysis. Receptors, Complement 3d / analysis. Retrospective Studies. T-Lymphocytes / chemistry. T-Lymphocytes / metabolism. T-Lymphocytes / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 International Society for Analytical Cytology.
  • (PMID = 16572417.001).
  • [ISSN] 1552-4949
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD3; 0 / Antigens, CD7; 0 / Receptors, Complement 3d; EC 3.1.3.48 / Antigens, CD45; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


23. Strupp C, Germing U, Aivado M, Kündgen A, Fenk R, Hünerlitürkoglu A, Kobbe G, Haas R, Gattermann N: The ratio between CD4+ and CD8+ cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide. Leuk Lymphoma; 2005 Jul;46(7):999-1006
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ratio between CD4+ and CD8+ cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide.
  • Thalidomide is thought to have anti-angiogenic and immunomodulatory properties, including suppression of tumor necrosis factor-alpha, effects on interleukins and interferons, down-regulation of some cell adhesion molecules, and changes in the proportion of lymphocyte subsets.
  • We examined the effect of thalidomide on T-lymphocyte subsets in 18 patients with MDS, 6 patients with MM, 4 patients with IM, and 3 patients with angioimmunoblastic lymphoma (AILD).
  • These patients had either a relapse or progressive disease following cytotoxic chemotherapy including high-dose chemotherapy with autologous stem cell support.
  • T-lymphocyte subsets (CD4+, CD8+) were measured by fluorescence-activated cell sorter (FACS) before and during treatment with thalidomide.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. CD4-CD8 Ratio. Hematologic Diseases / drug therapy. Immunosuppressive Agents / therapeutic use. Thalidomide / therapeutic use
  • [MeSH-minor] Adult. Aged. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Female. Humans. Male. Middle Aged. Stem Cell Transplantation

  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019550.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Immunosuppressive Agents; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


24. Geissinger E, Bonzheim I, Krenács L, Roth S, Reimer P, Wilhelm M, Müller-Hermelink HK, Rüdiger T: Nodal peripheral T-cell lymphomas correspond to distinct mature T-cell populations. J Pathol; 2006 Oct;210(2):172-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodal peripheral T-cell lymphomas correspond to distinct mature T-cell populations.
  • Peripheral T-cell lymphomas (PTCL) have not been successfully correlated with specific developmental stages of reactive T-cells.
  • In this study, we evaluated lymph node biopsies from eight PTCL-not otherwise specified (PTCL-NOS), seven angioimmunoblastic T-cell lymphomas (AILT), and 15 anaplastic large cell lymphomas (ALCL).
  • Detection of tumour cells with antibodies that recognize specific rearranged T-cell receptor Vbeta segments allowed us to investigate the expression of various differentiation-associated molecules.
  • All AILT and ALCL showed a homogeneous effector cell phenotype (CD45RA(-)/CD45R0(+)/CD27(-)), but differed in the cytotoxic and activation markers expressed.
  • Several (5/8) PTCL-NOS clustered together; these cases all exhibited a CD4(+) central memory cell phenotype (CD45RA(-)/CD45R0(+)/CD27(+)) and four expressed the lymph node homing receptor CCR7.
  • In conclusion, AILT and ALCL tumour cells correspond to different subsets of effector cells, while a subset of PTCL-NOS correlates with a non-effector T-cell population.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / immunology. T-Lymphocyte Subsets / immunology
  • [MeSH-minor] Antigens, CD27 / metabolism. Antigens, CD45 / metabolism. CD4-Positive T-Lymphocytes / immunology. Cell Differentiation / immunology. Cluster Analysis. Humans. Immunoblastic Lymphadenopathy / immunology. Immunologic Memory. Immunophenotyping. Lymphoma, Large-Cell, Anaplastic / immunology. Receptors, CCR7. Receptors, Chemokine / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16924587.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD27; 0 / CCR7 protein, human; 0 / Receptors, CCR7; 0 / Receptors, Chemokine; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


25. Leich E, Haralambieva E, Zettl A, Chott A, Rüdiger T, Höller S, Müller-Hermelink HK, Ott G, Rosenwald A: Tissue microarray-based screening for chromosomal breakpoints affecting the T-cell receptor gene loci in mature T-cell lymphomas. J Pathol; 2007 Sep;213(1):99-105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue microarray-based screening for chromosomal breakpoints affecting the T-cell receptor gene loci in mature T-cell lymphomas.
  • The pathogenesis of mature T-cell non-Hodgkin lymphomas (T-NHLs) is poorly understood.
  • Analogous to B-cell lymphomas, in which the immunoglobulin (IgH) receptor loci are frequently targeted by chromosomal translocations, the T-cell receptor (TCR) gene loci are affected by translocations in a subset of precursor T-cell malignancies.
  • In a large-scale analysis of 245 paraffin-embedded mature T-NHLs, arranged in a tissue microarray format and using improved FISH assays for the detection of breakpoints in the TCRalpha/delta, TCRbeta, and TCRgamma loci, we provide evidence that mature T-NHLs other than T-cell prolymphocytic leukaemia (T-PLL) also occasionally show a chromosomal rearrangement that involves the TCRalpha/delta locus.
  • In particular, one peripheral T-cell lymphoma (not otherwise specified, NOS) with the morphological variant of Lennert lymphoma displayed a chromosomal translocation t(14;19) involving the TCRalpha/delta and the BCL3 loci.
  • A second case, an angio-immunoblastic T-cell lymphoma (AILT), carried an inv(14)(q11q32) affecting the TCRalpha/delta and IgH loci.
  • FISH signal constellations as well as concomitant comparative genomic hybridization (CGH) data were also suggestive of the occurrence of an isochromosome 7, previously described to be pathognomonic for hepatosplenic T-cell lymphomas, in rare cases of enteropathy-type T-cell lymphoma.
  • [MeSH-major] Chromosome Breakage. Gene Rearrangement, T-Lymphocyte. Genes, T-Cell Receptor. Lymphoma, T-Cell / genetics
  • [MeSH-minor] Case-Control Studies. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 19. Chromosomes, Human, Pair 7. Gene Expression Profiling. Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor. Gene Rearrangement, delta-Chain T-Cell Antigen Receptor. Humans. Immunoglobulin Heavy Chains / genetics. In Situ Hybridization, Fluorescence. Oligonucleotide Array Sequence Analysis. Paraffin Embedding. Proto-Oncogene Proteins / genetics. Transcription Factors / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17582237.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Proto-Oncogene Proteins; 0 / Transcription Factors; 0 / proto-oncogene protein bcl-3
  •  go-up   go-down


26. Matsui K, Adachi M, Tominaga T, Shinohara K, Kamei T: Angioimmunoblastic T cell lymphoma associated with reversible myelofibrosis. Intern Med; 2008;47(21):1921-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T cell lymphoma associated with reversible myelofibrosis.
  • Biopsy of the lymph node demonstrated angioimmunoblastic T cell lymphoma (AITL) with the loss of normal architecture, proliferation of neoplastic T cells, small vessels mixed with eosinophils and plasma cells.
  • After chemotherapy, remission of lymphoma was achieved.
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis. Primary Myelofibrosis / diagnosis
  • [MeSH-minor] Humans. Lymphoma, T-Cell / complications. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / drug therapy. Male. Middle Aged

  • Genetic Alliance. consumer health - Myelofibrosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18981638.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


27. Jones B, Vun Y, Sabah M, Egan CA: Toxic epidermal necrolysis secondary to angioimmunoblastic T-cell lymphoma. Australas J Dermatol; 2005 Aug;46(3):187-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxic epidermal necrolysis secondary to angioimmunoblastic T-cell lymphoma.
  • A 67-year-old man presented with a history of lymphadenopathy, fevers and separate skin eruptions of erythrodermic spongiotic dermatitis initially and subsequent toxic epidermal necrolysis.
  • Initial lymph node biopsies showed non-specific granulomatous changes, and skin biopsies and bone marrow aspirate were not diagnostic.
  • Due to persisting lymphadenopathy, further lymph node biopsy led to the diagnosis of angioimmunoblastic T-cell lymphoma, a rare form of peripheral T-cell lymphoma with a poor prognosis.
  • At the time of diagnosis his condition deteriorated rapidly and he died soon after.
  • [MeSH-major] Head and Neck Neoplasms / complications. Immunoblastic Lymphadenopathy / complications. Lymphoma, T-Cell / complications. Stevens-Johnson Syndrome / etiology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008654.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Immunoglobulins, Intravenous
  •  go-up   go-down


28. Bayerl MG, Hennessy J, Ehmann WC, Bagg A, Rosamilia L, Clarke LE: Multiple cutaneous monoclonal B-cell proliferations as harbingers of systemic angioimmunoblastic T-cell lymphoma. J Cutan Pathol; 2010 Jul;37(7):777-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple cutaneous monoclonal B-cell proliferations as harbingers of systemic angioimmunoblastic T-cell lymphoma.
  • We describe a 66-year-old man initially diagnosed with primary cutaneous marginal zone B-cell lymphoma who developed four additional monoclonal/monotypic B-cell lymphoid proliferations and a systemic angioimmunoblastic T-cell lymphoma over the course of 19 months.
  • Through retrospective analysis, we identified the evolution of a T-cell clone within the background of clinically and pathologically dominant cutaneous B-cell tumors.
  • In terms of clinical practice, this case supports that patients diagnosed with multiple clonal B-cell proliferation need thorough investigation and close clinical follow up to identify a coexistent or evolving systemic lymphoma, in particular, peripheral T-cell lymphomas of follicular T-helper cell type, such as angioimmunoblastic T-cell lymphoma.
  • Biologically, this case offers unique insight into the interactions between B-cell and T-cell lineages in lymphoid neoplasia.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, T-Cell, Cutaneous / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Immunoglobulin Heavy Chains / genetics. Immunohistochemistry. Male. Polymerase Chain Reaction. Receptors, Antigen, T-Cell / genetics

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19702684.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


29. Ramasamy K, Lim Z, Pagliuca A, Salisbury JR, Mufti GJ, Devereux S: Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone. Haematologica; 2006 Aug;91(8 Suppl):ECR44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone.
  • Angioimmunoblastic T cell lymphoma (AITL) is a peripheral T-cell lymphoma characterized morphologically by lymphadenopathy with a polymorphic infiltrate, marked vascular and follicular dendritic cell proliferation.
  • Patients usually present with advanced disease and the overall prognosis is poor.
  • [MeSH-major] Dexamethasone / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy. Thalidomide / therapeutic use

  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16923528.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


30. Takahashi T, Maruyama R, Mishima S, Inoue M, Kawakami K, Onishi C, Miyake T, Tanaka J, Nabika T, Ishikura H: Small bowel perforation caused by Epstein-Barr virus-associated B cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma. J Clin Exp Hematop; 2010;50(1):59-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel perforation caused by Epstein-Barr virus-associated B cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma.
  • On rare occasions, secondary Epstein-Barr virus (EBV)-associated B cell lymphoma can develop in a patient with angioimmunoblastic T-cell lymphoma (AITL).
  • We report a case of a 66-year-old Japanese woman who developed diffuse large B-cell lymphoma (DLBCL) in her small intestine after chemotherapy for AITL.
  • In situ hybridization for EBV-encoded RNA revealed positivity in the lymphoma cells.
  • The lymph nodes diagnosed as AITL were negative for EBV infection and there was no coexistence of B cell neoplasms in them.
  • We thought small bowel perforation in this case was caused by EBV-associated B cell lymphoma secondary to AITL.
  • Our case showed a remarkable deficiency of cellular immunity after chemotherapy, which we postulate was related to the cause of occurrence of B-cell lymphoma.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Intestinal Neoplasms / complications. Intestinal Perforation / etiology. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, T-Cell / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20505277.001).
  • [ISSN] 1880-9952
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


31. Lin HN, Liu CY, Hong YC, Pai JT, Yang CF, Yu YB, Hsiao LT, Chiou TJ, Liu JH, Gau JP, Tzeng CH, Chen PM: Clinical features and prognostic factors of angioimmunoblastic T-cell lymphoma in Taiwan: a single-institution experience. Leuk Lymphoma; 2010 Dec;51(12):2208-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and prognostic factors of angioimmunoblastic T-cell lymphoma in Taiwan: a single-institution experience.
  • Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma that carries a poor prognosis.
  • Among all patients, 67.7% were Ann Arbor stage III or IV, 58.1% presented with B symptoms, 48.4% had hypoalbuminenia (<35 g/L), and 63.3% had elevated lactate dehydrogenase (LDH) at diagnosis.
  • Despite the prognosis being generally poor, patients with AITL should be treated with the goal of achieving CR, regardless of anthracycline- or non-anthracycline-based chemotherapy.
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2011 Jan;52(1):1-2 [21133725.001]
  • (PMID = 21054150.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Viallard JF, Lazaro E, Lafon ME, Pellegrin JL: Successful cidofovir therapy of progressive multifocal leukoencephalopathy preceding angioimmunoblastic T-cell lymphoma. Leuk Lymphoma; 2005 Nov;46(11):1659-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful cidofovir therapy of progressive multifocal leukoencephalopathy preceding angioimmunoblastic T-cell lymphoma.
  • Progressive multifocal leukoencephalopathy (PML) is a subacute demyelinating infectious disease, caused by the human polyomavirus JC (JCV), that usually occurs in immunocompromised patients.
  • In this setting, PML has been observed in increasing numbers of patients with hematological malignancies, mostly lymphoproliferative B-cell disorders.
  • We report the successful use of cidofovir in a patient who developed PML 6 months before angioimmunoblastic T-cell lymphoma (AITL) was diagnosed.
  • Progressive multifocal leukoencephalopathy (PML) is a subacute demyelinating infectious disease, caused by the human polyomavirus JC (JCV), that usually occurs in immunocompromised patients.
  • In this setting, PML has been observed in increasing numbers of patients with hematological malignancies, mostly lymphoproliferative B-cell disorders.
  • We report the successful use of cidofovir in a patient who developed PML 6 months before angioimmunoblastic T-cell lymphoma (AITL) was diagnosed.
  • [MeSH-major] Cytosine / analogs & derivatives. Immunoblastic Lymphadenopathy / complications. Leukoencephalopathy, Progressive Multifocal / drug therapy. Lymphoma, T-Cell / complications. Organophosphonates / therapeutic use
  • [MeSH-minor] Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Nerve Fibers, Myelinated / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Progressive multifocal leukoencephalopathy.
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334909.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


33. Saito A, Miyazawa Y, Isoda A, Hatsumi N, Matsumoto M, Kojima M, Sawamura M: [Clinicopathological analysis of patients with angioimmunoblastic T-cell lymphoma (AILT)]. Rinsho Ketsueki; 2008 Feb;49(2):82-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological analysis of patients with angioimmunoblastic T-cell lymphoma (AILT)].
  • We retrospectively analyzed the clinical course and prognosis of 11 patients with angioimmunoblastic T-cell Lymphoma (AILT).
  • The disease can be classified into three categories based on histological findings: 3 cases of AILT with hyperplastic germinal centers, 4 cases of typical AILT, and 4 cases of AILT with numerous clear cells.
  • As the initial therapy, 10 patients received combination chemotherapy and only 1 patient received autologous peripheral blood stem cell transplantation.
  • Patients with AILT demonstrating hyperplastic germinal centers and no bone marrow infiltration were able to achieve long-term survival.
  • The survival time of AILT demonstrated a wide range.
  • [MeSH-major] Immunoblastic Lymphadenopathy / therapy. Lymphoma, T-Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341037.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


34. Tan BT, Warnke RA, Arber DA: The frequency of B- and T-cell gene rearrangements and epstein-barr virus in T-cell lymphomas: a comparison between angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified with and without associated B-cell proliferations. J Mol Diagn; 2006 Sep;8(4):466-75; quiz 527
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The frequency of B- and T-cell gene rearrangements and epstein-barr virus in T-cell lymphomas: a comparison between angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified with and without associated B-cell proliferations.
  • We report on a series of 58 cases of angioimmunoblastic T-cell lymphoma (AILT) and 59 cases of peripheral T-cell lymphoma, unspecified (PTCL-NOS).
  • Subsets of cases from both diagnostic groups were complicated by associated B-cell proliferations, and we performed B- and T-cell clonality studies and in situ hybridization for Epstein-Barr virus (EBV) to investigate the relationship between B-cell proliferation, B-cell clonality, and EBV.
  • Using multiplex polymerase chain reaction assays based on the BIOMED-2 collaborative study, we detected TCRgamma T-cell clones in 78 and 81% of AILT and PTCL-NOS cases, respectively, and IGH B-cell clones in 34 and 35% of AILT and PTCL-NOS cases, respectively.
  • The majority of cases contained EBV-positive cells, including 50% of AILT and 57% of PTCL-NOS cases, and cases with B-cell proliferations were more often EBV-positive.
  • Although a relatively high rate of B-cell clonality has been shown for AILT, our findings for PTCL-NOS differ from previous reports in that B-cell clonality was relatively frequent.
  • Overall, a positive B-cell clone correlated, in part, with the presence of a B-cell proliferation but not with EBV.
  • Our findings demonstrate that B-cell clonality is a common finding in AILT and PTCL-NOS, and its presence should not negate the diagnosis established by morphologic, immunophenotypic, and clinical findings.
  • [MeSH-major] Gene Rearrangement, B-Lymphocyte. Gene Rearrangement, T-Lymphocyte. Herpesvirus 4, Human / genetics. Lymphoma, T-Cell / genetics. Lymphoma, T-Cell, Peripheral / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Cell Proliferation. Clone Cells. Female. Humans. Immunoglobulin Heavy Chains / genetics. Male. Middle Aged. Receptors, Antigen, T-Cell, gamma-delta / genetics

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Diagn. 2001 Nov;3(4):133-40 [11687596.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):661-9 [10666395.001]
  • [Cites] Am J Clin Pathol. 2002 Mar;117(3):368-79 [11888076.001]
  • [Cites] J Mol Diagn. 2002 May;4(2):81-9 [11986398.001]
  • [Cites] J Pathol. 2002 Oct;198(2):171-80 [12237876.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2134-41 [12357368.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):12-20 [12455048.001]
  • [Cites] Am J Clin Pathol. 2002 Dec;118(6):848-54 [12472277.001]
  • [Cites] Leuk Lymphoma. 2003 Jan;44(1):117-21 [12691150.001]
  • [Cites] J Mol Diagn. 2003 May;5(2):82-7 [12707372.001]
  • [Cites] Leuk Lymphoma. 2003 May;44(5):807-13 [12802918.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Blood. 1983 Jun;61(6):1138-45 [6404327.001]
  • [Cites] Blood. 1986 Jan;67(1):1-11 [3079640.001]
  • [Cites] Am J Clin Pathol. 1986 Apr;85(4):490-3 [2420169.001]
  • [Cites] Leukemia. 1987 Mar;1(3):235 [3669744.001]
  • [Cites] Am J Pathol. 1988 Dec;133(3):549-56 [2849301.001]
  • [Cites] Clin Chim Acta. 1991 Apr;198(1-2):93-174 [1863986.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1789-95 [1373088.001]
  • [Cites] Histopathology. 1993 Feb;22(2):145-9 [8384155.001]
  • [Cites] Blood. 1993 Jul 1;82(1):217-23 [8391874.001]
  • [Cites] Histopathology. 1994 Feb;24(2):115-22 [8181803.001]
  • [Cites] Blood. 1994 Jul 15;84(2):574-81 [8025283.001]
  • [Cites] Virchows Arch. 1994;424(6):593-600 [8055152.001]
  • [Cites] J Pathol. 1994 Dec;174(4):233-42 [7884584.001]
  • [Cites] Leuk Lymphoma. 1995 Sep;19(1-2):1-12 [8574154.001]
  • [Cites] J Clin Pathol. 1995 Nov;48(11):1045-50 [8543629.001]
  • [Cites] Am J Surg Pathol. 1998 Aug;22(8):956-64 [9706975.001]
  • [Cites] J Pathol. 1998 May;185(1):79-85 [9713363.001]
  • [Cites] Mol Diagn. 1999 Jun;4(2):119-33 [10462627.001]
  • [Cites] Hematol Oncol. 2004 Dec;22(4):169-77 [16134192.001]
  • [Cites] J Mol Diagn. 2005 Oct;7(4):495-503 [16237219.001]
  • [Cites] Am J Clin Pathol. 2000 Aug;114(2):236-47 [10941339.001]
  • [Cites] Mod Pathol. 2000 Dec;13(12):1269-79 [11144922.001]
  • [Cites] Diagn Mol Pathol. 2001 Jun;10(2):69-77 [11385314.001]
  • [Cites] Blood. 2002 Jan 15;99(2):627-33 [11781247.001]
  • [CommentIn] J Mol Diagn. 2006 Sep;8(4):426-9; quiz 526-7 [16931581.001]
  • (PMID = 16931587.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Receptors, Antigen, T-Cell, gamma-delta
  • [Other-IDs] NLM/ PMC1867616
  •  go-up   go-down


35. Miyazaki K, Masuya M, Yamaguchi M, Isaka S, Nakase K, Kobayashi T, Nakamura S, Shiku H: [Angioimmunoblastic T-cell lymphoma occurring four months after autologous peripheral blood stem cell transplantation with high-dose chemotherapy for follicular lymphoma]. Rinsho Ketsueki; 2005 Sep;46(9):1065-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic T-cell lymphoma occurring four months after autologous peripheral blood stem cell transplantation with high-dose chemotherapy for follicular lymphoma].
  • A 62-year-old Japanese woman was diagnosed as having follicular lymphoma (FL, grade 3, CS IIIA, IPI high-intermediate risk) in May 1998.
  • High-dose etoposide was used for autologous peripheral stem cell mobilization.
  • In May 1999, she underwent high-dose chemotherapy with autologous peripheral blood stem cell transplantation (auto-PBSCT).
  • Four months after the auto-PBSCT, bilateral cervical lymphadenopathy developed.
  • Histopathological findings from a biopsied cervical lymph node showed angioimmunoblastic T-cell lymphoma (AILT).
  • The patient was treated with modified CVP therapy, and she is alive with no evidence of lymphoma five years after auto-PBSCT.
  • Clinical and histopathological findings showed that the FL and AILT in this case were not concomitant.
  • It is thought that in this case, the AILT developed as a post-transplant lymphoproliferative disorder after auto-PBSCT for the FL.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / adverse effects. Etoposide / adverse effects. Immunoblastic Lymphadenopathy / etiology. Lymphoma, Follicular / therapy. Lymphoma, T-Cell / etiology. Peripheral Blood Stem Cell Transplantation / adverse effects


36. Khong PL, Pang CB, Liang R, Kwong YL, Au WY: Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol; 2008 Aug;87(8):613-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies.
  • Fluorine-18 fluorodeoxyglucose (FDG)-positron emission tomography (PET) is useful in Hodgkin and B-cell lymphomas.
  • Few data exist on T-cell and natural killer (NK)-cell lymphomas.
  • Thirty consecutive T-cell and NK-cell lymphomas were investigated with PET-computerized tomography (CT).
  • In 12 NK-cell lymphomas, all nasal/extranasal lesions were FDG-avid.
  • In two NK-cell lymphomas, PET did not detect morphologically occult marrow infiltration uncovered by in situ hybridisation for Epstein-Barr-virus-encoded small RNA.
  • In angioimmunoblastic lymphoma (n = 7), peripheral T-cell lymphoma, unspecified (PTCL-U, n = 4) and anaplastic large cell lymphoma (ALCL, n = 3), involved nodal/extranodal sites shown on CT and/or biopsy were concordantly PET-positive.
  • In one case of T-cell large granular lymphocyte leukaemia, marrow, nodal and bowel infiltrations were not FDG-avid.
  • These observations defined the pre-treatment value of PET-CT in T-cell and NK-cell lymphomas.
  • [MeSH-major] Fluorodeoxyglucose F18. Killer Cells, Natural / radionuclide imaging. Lymphoma, T-Cell / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Disease Progression. Female. Humans. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18509641.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


37. Troxell ML, Schwartz EJ, van de Rijn M, Ross DT, Warnke RA, Higgins JP, Natkunam Y: Follicular dendritic cell immunohistochemical markers in angioimmunoblastic T-cell lymphoma. Appl Immunohistochem Mol Morphol; 2005 Dec;13(4):297-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular dendritic cell immunohistochemical markers in angioimmunoblastic T-cell lymphoma.
  • Angioimmunoblastic T-cell lymphoma is characterized by a paracortical proliferation of medium to large neoplastic T cells, often with clear cytoplasm, in a background of arborizing high endothelial venules, many surrounded by follicular dendritic cells (FDCs).
  • The authors stained a collection of 45 angioimmunoblastic T-cell lymphomas with CD21, CD23, CNA.42, cystatin A, and fascin for direct comparison of FDC staining characteristics in this setting.
  • CD21 highlighted the expected dendritic network of cell processes, within residual follicles and outside of follicles, often adjacent to proliferating vessels.
  • Cystatin A stained the cytoplasm of follicular dendritic cells within and outside of follicles; however, staining was often not sharply localized to dendritic cell processes, and scoring was further complicated by reactivity with other cell types in over half of the cases.
  • Likewise, fascin stained a variety of cell types, including strong staining of interdigitating dendritic-like cells, moderate staining of endothelial cells, and only weak staining of follicular dendritic cells within and outside of follicles.
  • Thus, CD21 remains the most reliable marker of follicular dendritic cells in angioimmunoblastic T-cell lymphoma.

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16280657.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Carrier Proteins; 0 / Cystatins; 0 / Cysteine Proteinase Inhibitors; 0 / Microfilament Proteins; 0 / Receptors, Complement 3d; 0 / Receptors, IgE; 146808-54-0 / fascin
  •  go-up   go-down


38. Iannitto E, Ferreri AJ, Minardi V, Tripodo C, Kreipe HH: Angioimmunoblastic T-cell lymphoma. Crit Rev Oncol Hematol; 2008 Dec;68(3):264-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma.
  • Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive neoplasm clinically characterized by sudden onset of constitutional symptoms, lymphadenopathy, hepatosplenomegaly, frequent autoimmune phenomena, particularly hemolytic anemia and thrombocytopenia, and polyclonal hypergammaglobulinemia.
  • The neoplastic CD4+ T-cells represent a minority of the lymph node cell population; its detection is facilitated by the aberrant expression of CD10.
  • Almost all cases arbor an EBV infected B-cell population.
  • Patients with AITL have a poor prognosis with conventional treatment, with a median overall survival of less than 3 years.
  • Patients achieving a good clinical response seem beneficiate from a consolidation with high-dose therapy and autologous stem cell transplantation.
  • [MeSH-major] Immunosuppressive Agents / therapeutic use. Lymphoma, T-Cell / drug therapy. Stem Cell Transplantation. Thalidomide / therapeutic use
  • [MeSH-minor] B-Lymphocytes / metabolism. B-Lymphocytes / pathology. B-Lymphocytes / virology. CD4-Positive T-Lymphocytes / metabolism. CD4-Positive T-Lymphocytes / pathology. Cell Proliferation. Dendritic Cells / metabolism. Dendritic Cells / pathology. Epstein-Barr Virus Infections / metabolism. Epstein-Barr Virus Infections / mortality. Epstein-Barr Virus Infections / pathology. Epstein-Barr Virus Infections / therapy. Female. Herpesvirus 4, Human. Humans. Lymph Nodes / metabolism. Lymph Nodes / pathology. Male. Neprilysin / metabolism. Survival Rate. Transplantation, Autologous

  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18684638.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 4Z8R6ORS6L / Thalidomide; EC 3.4.24.11 / Neprilysin
  • [Number-of-references] 57
  •  go-up   go-down


39. Kojima M, Sugiura I, Itoh H, Shimizu K, Murayama K, Motoori T, Shimano S, Masawa N, Nakamura S: Histological varieties of Epstein-Barr virus-related lymph node lesion resembling autoimmune disease-like clinicopathological findings in middle-aged and elderly patients: a study of six cases. Pathol Res Pract; 2006;202(8):609-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological varieties of Epstein-Barr virus-related lymph node lesion resembling autoimmune disease-like clinicopathological findings in middle-aged and elderly patients: a study of six cases.
  • Six cases were studied to further clarify clinicopathological findings of Epstein-Barr virus (EBV)-related lymph node lesions showing autoimmune disease-like clinicopathological findings (EBVAID) in middle-aged and elderly patients.
  • The patients, four males and two females, ranged in age from 53 to 74 years, with a median age of 62 years.
  • Clinically, they were characterized by systemic lymphadenopathy, "B"symptoms, polyclonal hypergammaglobulinemia, elevated serum lactate dehydrogenase and a transient presence of various autoantibodies, as well as an infrequent presence of atypical lymphocytosis in peripheral blood.
  • Histologically, three patterns could be delineated: pattern A, follicular hyperplasia with pronounced arborizing vasculature in the expanded paracortex (n=3); pattern B, follicular hyperplasia with pronounced interfollicular B-immunoblastic/plasma cell proliferation (n=2); and pattern C, paracortical hyperplasia containing numerous large transformed lymphocytes (n=1).
  • Polymerase chain reaction analysis demonstrated that neither clonal rearrangement of T-cell receptor gamma-chain nor immunoglobulin heavy-chain rearrangement was detected in the three cases examined.
  • Although EBVAID appears to be rare in middle-aged and older adults, EBVAID exhibits histological variations and should be added to the differential diagnosis of various atypical or malignant lymphoproliferative disorders, in particular autoimmune-disease-associated lymphadenopathy and angioimmunoblastic T-cell lymphoma with a hyperplastic germinal center in middle-aged and elderly patients.
  • [MeSH-major] Autoimmune Diseases / pathology. Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human / isolation & purification. Lymph Nodes / pathology. Lymphoproliferative Disorders / pathology
  • [MeSH-minor] Aged. Autoantibodies / blood. Diagnosis, Differential. Female. Humans. Hypergammaglobulinemia / complications. Hypergammaglobulinemia / pathology. Immunoenzyme Techniques. In Situ Hybridization. L-Lactate Dehydrogenase / blood. Lymphatic Diseases / complications. Lymphatic Diseases / pathology. Lymphocytosis / complications. Lymphocytosis / pathology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16824704.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Autoantibodies; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


40. Sakai H, Tanaka H, Katsurada T, Yoshida Y, Okamoto E, Ohno H: Angioimmunoblastic T-cell lymphoma initially presenting with replacement of bone marrow and peripheral plasmacytosis. Intern Med; 2007;46(7):419-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma initially presenting with replacement of bone marrow and peripheral plasmacytosis.
  • A 73-year-old man presented with lymphadenopathy, hepatosplenomegaly, and a variety of hematological and immunological abnormalities.
  • Circulating lymphoplasmacytic/immunoblastic cells showed an early plasma cell immunophenotype on flow cytometric analysis.
  • Combination of these observations indicated that the underlying disorder of this patient was angioimmunoblastic T-cell lymphoma (AITL); postmortem pathology was consistent with progression of peripheral T-cell lymphoma.
  • Even in the absence of definitive lymph node biopsy, the appearance of the bone marrow and the peripheral blood can lead to the diagnosis of AITL.
  • [MeSH-major] Bone Marrow / pathology. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / pathology. Plasma Cells / pathology
  • [MeSH-minor] Aged. Autopsy. Biopsy, Needle. Diagnosis, Differential. Disease Progression. Fatal Outcome. Humans. Immunohistochemistry. Male. Risk Assessment. Severity of Illness Index

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409610.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


41. Jarrett R, Walk N, Castellano-Sanchez AA, Kreisel FH: A 68-year-old man with shortness of breath and peripheral edema. Angioimmunoblastic T-cell lymphoma. Arch Pathol Lab Med; 2006 Feb;130(2):219-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 68-year-old man with shortness of breath and peripheral edema. Angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Dyspnea / diagnosis. Edema / diagnosis. Immunoblastic Lymphadenopathy / diagnosis. Lymphoma, T-Cell, Peripheral / diagnosis. Pleural Effusion / diagnosis

  • Genetic Alliance. consumer health - Edema.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Breathing Problems.
  • MedlinePlus Health Information. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16454568.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucocorticoids
  •  go-up   go-down


42. Hagberg H, Pettersson M, Bjerner T, Enblad G: Treatment of a patient with a nodal peripheral T-cell lymphoma (angioimmunoblastic T-Cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4). Med Oncol; 2005;22(2):191-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of a patient with a nodal peripheral T-cell lymphoma (angioimmunoblastic T-Cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4).
  • A patient with a CD4+ refractory peripheral T-cell lymphoma (PTL), subtype angioimmunoblastic T-cell lymphoma (AILD), was treated with a human monoclonal anti-CD4 antibody (HuMax-CD4) iv once weekly for 10 wk.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD4 / immunology. Immunoblastic Lymphadenopathy / therapy. Immunotherapy. Lymph Nodes / drug effects. Lymphoma, T-Cell, Peripheral / therapy

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1996 Nov;95(2):327-38 [8904888.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2848-55 [12019163.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1721-6 [11535503.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):681-91 [12780782.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2920-4 [15070664.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4267-72 [12543862.001]
  • [Cites] Blood. 1996 Feb 1;87(3):893-9 [8562959.001]
  • [Cites] Arch Dermatol. 2003 Nov;139(11):1433-9 [14623703.001]
  • (PMID = 15965283.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD4
  •  go-up   go-down


43. Tzankov AS, Went PT, Münst S, Papadopoulos T, Jundt G, Dirnhofer SR: Rare expression of BSAP (PAX-5) in mature T-cell lymphomas. Mod Pathol; 2007 Jun;20(6):632-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare expression of BSAP (PAX-5) in mature T-cell lymphomas.
  • Lineage determination in lymphomas is based on the assessment of lineage-specific markers, such as the B-cell-specific activator protein of the paired box family (BSAP, PAX-5) for the B-cell lineage.
  • BSAP is thought to be expressed exclusively in B cells from the pro-B- to the mature B-cell stage and then silenced in plasma cells.
  • BSAP has oncogenic potential and experimental evidence shows that the T-cell lineage is prone to this effect.
  • Herein, we report on a BSAP-positive peripheral T-cell lymphoma with monoclonal T-cell receptor gamma-gene rearrangement.
  • To assess the relative frequency of BSAP expression in mature T-cell lymphomas, we constructed and examined a tissue microarray consisting of 43 angioimmunoblastic T-cell lymphomas and peripheral T-cell lymphomas and detected no additional BSAP-positive cases.
  • To conclude, BSAP can probably contribute to T-cell lymphomagenesis not only in vitro, but also in vivo.
  • It is rarely expressed in peripheral T-cell lymphoma, thus its detection on lymphoid malignancies cannot be considered definitively lineage specific.
  • [MeSH-major] B-Cell-Specific Activator Protein / biosynthesis. Lymphoma, T-Cell / metabolism
  • [MeSH-minor] Aged. Biomarkers, Tumor / biosynthesis. Cell Lineage. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Lymphoma, T-Cell, Peripheral / metabolism. Male. Middle Aged. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431414.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Biomarkers, Tumor; 0 / PAX5 protein, human
  •  go-up   go-down


44. Sung CO, Ko YH, Park S, Kim K, Kim W: Immunoreactivity of CD99 in non-Hodgkin's lymphoma: unexpected frequent expression in ALK-positive anaplastic large cell lymphoma. J Korean Med Sci; 2005 Dec;20(6):952-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoreactivity of CD99 in non-Hodgkin's lymphoma: unexpected frequent expression in ALK-positive anaplastic large cell lymphoma.
  • To verify the spectrum of CD99-expressing lymphoid malignancy, an immunohistochemical study for CD99 was carried out in 182 cases of non-Hodgkin's lymphoma, including 21 lymphoblastic lymphomas, 11 small lymphocytic lymphomas, 9 mantle cell lymphomas, 12 follicular lymphomas, 37 diffuse large B cell lymphomas, 18 Burkitt's lymphomas, 28 NK/T-cell lymphomas, 8 angioimmunoblastic T-cell lymphomas, 23 peripheral T-cell lymphomas, unspecified, and 15 systemic anaplastic large cell lymphomas.
  • CD99 was positive in all T-lymphoblastic lymphomas and in 60% of B-lymphoblastic lymphomas.
  • Majority of T and NK cell lymphomas were negative for CD99, except anaplastic large cell lymphomas (ALCLs).
  • Of the mature B-cell lymphomas, 5.4% (2/37) of diffuse large B cell lymphomas and 11.1% (2/18) of Burkitt's lymphomas expressed CD99.
  • In conclusion, CD99 is infrequently expressed in mature B and T cell lymphomas, except ALK-positive ALCL.
  • High expression of CD99 in ALK-positive ALCL is unexpected finding and its biologic and clinical significances have yet to be clarified.
  • [MeSH-major] Antigens, CD / metabolism. Cell Adhesion Molecules / metabolism. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, Non-Hodgkin / immunology. Protein-Tyrosine Kinases / metabolism

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:33-8 [1646624.001]
  • [Cites] Am J Pathol. 1990 Nov;137(5):1047-57 [2173409.001]
  • [Cites] Histopathology. 1993 Dec;23(6):557-61 [8314240.001]
  • [Cites] Hum Pathol. 1994 Apr;25(4):396-9 [8163272.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):486-94 [7513503.001]
  • [Cites] Blood. 1996 May 15;87(10):4340-7 [8639794.001]
  • [Cites] Hum Pathol. 1996 Dec;27(12):1273-6 [8958297.001]
  • [Cites] Mod Pathol. 1997 Apr;10(4):277-82 [9110287.001]
  • [Cites] J Immunol. 1997 Sep 1;159(5):2250-8 [9278313.001]
  • [Cites] Mod Pathol. 1998 Aug;11(8):769-73 [9720506.001]
  • [Cites] J Immunol. 1998 Nov 1;161(9):4671-8 [9794396.001]
  • [Cites] Br J Haematol. 1999 Jun;105(3):690-5 [10354133.001]
  • [Cites] J Korean Med Sci. 2005 Feb;20(1):50-5 [15716602.001]
  • [Cites] Mod Pathol. 2000 Apr;13(4):452-8 [10786814.001]
  • [Cites] Virchows Arch. 2000 Sep;437(3):270-4 [11037347.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):527-35 [11485911.001]
  • [Cites] Leuk Lymphoma. 2001 Aug;42(4):587-94 [11697486.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4540-6 [12036886.001]
  • [Cites] J Korean Med Sci. 2002 Aug;17(4):483-9 [12172043.001]
  • [Cites] FEBS Lett. 2003 Nov 20;554(3):478-84 [14623115.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):353-64 [15093542.001]
  • [Cites] Oncogene. 2004 Jul 22;23(33):5664-74 [15184883.001]
  • [Cites] Cancer Res. 1988 Nov 1;48(21):6127-31 [2844401.001]
  • [Cites] Blood. 1994 Jan 15;83(2):415-25 [7506950.001]
  • (PMID = 16361803.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Other-IDs] NLM/ PMC2779325
  •  go-up   go-down


45. Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T, Kucuk C, Geng H, Deffenbacher K, Smith L, Dybkaer K, Nakamura S, Seto M, Delabie J, Berger F, Loong F, Au WY, Ko YH, Sng I, Armitage JO, Chan WC, International Peripheral T-Cell Lymphoma Project: Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood; 2010 Feb 4;115(5):1026-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma.
  • Peripheral T-cell lymphoma (PTCL) is often challenging to diagnose and classify.
  • Gene expression profiling was performed on 144 cases of PTCL and natural killer cell lymphoma and robust molecular classifiers were constructed for angioimmunoblastic T-cell lymphoma (AITL), anaplastic lymphoma kinase-positive (ALK(+)) anaplastic large-cell lymphoma (ALCL), and adult T-cell leukemia/lymphoma.
  • Many of the pathologic features and substantial components of the molecular signature of AITL are contributed by the follicular dendritic cells, B-cell, and other stromal components.
  • The expression of Th17-associated molecules in ALK(+) ALCL was noted and may represent aberrant activation of Th17-cell differentiation by abnormal cytokine secretion.
  • Adult T-cell leukemia/lymphoma has a homogeneous molecular signature demonstrating high expression of human T-lymphotropic virus type 1-induced genes.

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):317-26 [10830738.001]
  • [Cites] J Immunol. 2004 Feb 15;172(4):2006-10 [14764663.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Blood. 2002 Jan 15;99(2):627-33 [11781247.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2474-9 [14645001.001]
  • [Cites] PLoS Biol. 2004 Apr;2(4):E108 [15094809.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5154-7 [15100251.001]
  • [Cites] J Immunol. 2004 Jul 1;173(1):68-78 [15210760.001]
  • [Cites] Int J Oncol. 2004 Sep;25(3):605-13 [15289861.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1952-60 [15213097.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):334-43 [15480768.001]
  • [Cites] Nouv Rev Fr Hematol. 1990;32(1):39-41 [2140884.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Blood. 1997 Feb 1;89(3):948-56 [9028326.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2296-301 [9196143.001]
  • [Cites] J Pathol. 1997 Dec;183(4):432-9 [9496260.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Br J Haematol. 1998 Jun;101(4):703-11 [9674744.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7529-39 [15569983.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1204-13 [15471956.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):206-14 [15668271.001]
  • [Cites] Br J Haematol. 2005 May;129(3):366-72 [15842660.001]
  • [Cites] Lancet Oncol. 2005 Jun;6(6):440 [15925824.001]
  • [Cites] Hum Pathol. 2005 May;36(5):494-504 [15948116.001]
  • [Cites] Am J Surg Pathol. 2005 Oct;29(10):1284-93 [16160469.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2254-63 [16270046.001]
  • [Cites] Oncogene. 2006 Mar 9;25(10):1560-70 [16288225.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):490-4 [16625095.001]
  • [Cites] Nature. 2006 May 25;441(7092):431-6 [16724054.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2472-9 [16636342.001]
  • [Cites] Blood. 2006 Jul 1;108(1):218-27 [16527888.001]
  • [Cites] J Clin Invest. 2006 Dec;116(12):3171-82 [17111047.001]
  • [Cites] Hematol Oncol. 2006 Dec;24(4):175-80 [16783841.001]
  • [Cites] J Immunol. 2007 Jan 15;178(2):817-28 [17202343.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2156-64 [17077326.001]
  • [Cites] J Clin Invest. 2007 Mar;117(3):823-34 [17304354.001]
  • [Cites] Expert Opin Ther Targets. 2007 May;11(5):613-24 [17465721.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4952-63 [17284527.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3321-9 [17577022.001]
  • [Cites] Ann Oncol. 2007 Aug;18(8):1382-7 [17693651.001]
  • [Cites] BMC Genomics. 2007;8:230 [17623099.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10703-10 [18006812.001]
  • [Cites] Handb Exp Pharmacol. 2008;(181):151-60 [18071945.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] N Engl J Med. 2008 Nov 27;359(22):2313-23 [19038878.001]
  • [Cites] Nat Immunol. 2009 Jan;10(1):48-57 [19011627.001]
  • [Cites] Nat Rev Immunol. 2009 Jan;9(1):39-46 [19079134.001]
  • [Cites] Arthritis Rheum. 2009 Mar;60(3):750-9 [19248112.001]
  • [Cites] Blood. 2009 Apr 23;113(17):4016-26 [19131553.001]
  • [Cites] Curr Hematol Malig Rep. 2006 Jun;1(2):129-36 [20425343.001]
  • [Cites] Cancer. 2001 Feb 1;91(3):525-33 [11169934.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] J Immunol. 2002 May 1;168(9):4333-43 [11970975.001]
  • [Cites] J Biol Chem. 2002 May 10;277(19):16831-6 [11877449.001]
  • [Cites] J Mol Diagn. 2002 Aug;4(3):137-43 [12169674.001]
  • [Cites] J Natl Cancer Inst. 2003 Jan 1;95(1):14-8 [12509396.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6 [12900505.001]
  • [Cites] Blood. 2004 Jan 1;103(1):236-41 [12958063.001]
  • [CommentIn] Blood. 2010 Feb 4;115(5):919-20 [20133472.001]
  • (PMID = 19965671.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Databank-accession-numbers] GEO/ GSE19069
  • [Grant] United States / NCI NIH HHS / CA / U01 CA114778; United States / NCI NIH HHS / CA / CA36727; United States / NCRR NIH HHS / RR / P20 RR016469; United States / NCI NIH HHS / CA / 5U01/CA114778; United States / NCI NIH HHS / CA / P30 CA036727
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Other-IDs] NLM/ PMC2817630
  •  go-up   go-down


46. Jiang L, Yuan CM, Hubacheck J, Janik JE, Wilson W, Morris JC, Jasper GA, Stetler-Stevenson M: Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br J Haematol; 2009 Apr;145(2):173-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.
  • The anti-CD52 antibody alemtuzumab has been explored as a novel targeted therapy in T cell malignancies.
  • To assess the suitability of alemtuzumab therapy, we carried out a comprehensive study of CD52 expression using flow cytometry (FC) in 78 untreated patients diagnosed with mature T/natural killer (NK) cell neoplasms, including 34 adult T cell leukaemia/lymphomas (ATLL), two anaplastic large cell lymphomas (ALCL), three angioimmunoblastic T cell lymphomas (AITL), 16 cutaneous T cell lymphomas (CTCL), four extra-nodal T/NK cell lymphomas (ENT/NKCL), four hepatosplenic T cell lymphomas (HSTCL), 13 peripheral T cell lymphomas, not otherwise specified (PTCL-NOS) and two T-prolymphocytic leukaemia (T-PLL).
  • All AITL, HSTCL and T-PLL cases were CD52-positive and the frequency of CD52 expression was high in PTCL-NOS (92.3%), ATLL (94.1%) and CTCL (87.5%), implying a rational role for alemtuzumab in the treatment of these diseases; however, CD52 expression was low in ALCL (50%) and ENT/NKCL (25%).
  • FC testing for cell surface expression of CD52 is indicated in patients with T/NK cell malignancies being considered for alemtuzumab therapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antigens, CD / analysis. Antigens, Neoplasm / analysis. Antineoplastic Agents / therapeutic use. Glycoproteins / analysis. Lymphoma, T-Cell / immunology
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antigens, CD30 / analysis. Case-Control Studies. Flow Cytometry / methods. Humans. Immunophenotyping / methods. Killer Cells, Natural / immunology. Lymphoma, Extranodal NK-T-Cell / immunology. Prospective Studies. T-Lymphocytes / immunology. Treatment Failure

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Sep 15;98(6):1721-6 [11535503.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2316-23 [17581918.001]
  • [Cites] Med Oncol. 2002;19 Suppl:S27-32 [12180489.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4267-72 [12543862.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6453-7 [14559836.001]
  • [Cites] Blood. 2004 Jan 15;103(2):428-34 [12969983.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2920-4 [15070664.001]
  • [Cites] Eur J Immunol. 1988 Oct;18(10):1507-14 [2973413.001]
  • [Cites] Tissue Antigens. 1990 Mar;35(3):118-27 [2165283.001]
  • [Cites] Biochem J. 1993 Aug 1;293 ( Pt 3):633-40 [7688956.001]
  • [Cites] Mol Immunol. 1993 Aug;30(12):1089-96 [8366859.001]
  • [Cites] J Biol Chem. 1995 Mar 17;270(11):6088-99 [7890742.001]
  • [Cites] Cytometry. 1996 Oct 1;25(2):113-24 [8891441.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2667-72 [9215839.001]
  • [Cites] Leuk Res. 1998 Feb;22(2):185-91 [9593475.001]
  • [Cites] Biol Blood Marrow Transplant. 2004 Dec;10(12):867-76 [15570255.001]
  • [Cites] Eur J Pharmacol. 2005 May 9;514(2-3):217-24 [15910809.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2005 Sep 29;360(1461):1707-11 [16147535.001]
  • [Cites] Best Pract Res Clin Haematol. 2006;19(4):795-810 [16997184.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):7174-9 [17145843.001]
  • [Cites] Cytometry B Clin Cytom. 2007 Jan 15;72(1):34-42 [17051524.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Jun;60(1):129-34 [17406867.001]
  • [Cites] Haematologica. 2007 Apr;92(4):566-7 [17488672.001]
  • [Cites] Oncogene. 2007 May 28;26(25):3644-53 [17530018.001]
  • [Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]
  • (PMID = 19236377.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC011104-01
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, CD30; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab
  • [Other-IDs] NLM/ NIHMS416345; NLM/ PMC3487105
  •  go-up   go-down


47. Kyriakou C, Canals C, Goldstone A, Caballero D, Metzner B, Kobbe G, Kolb HJ, Kienast J, Reimer P, Finke J, Oberg G, Hunter A, Theorin N, Sureda A, Schmitz N, Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation: High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol; 2008 Jan 10;26(2):218-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
  • PURPOSE: Patients with angioimmunoblastic T-cell lymphoma (AITL) have poor prognoses with current conventional chemotherapy.
  • The aim of this study was to evaluate the effect of high-dose therapy (HDT) followed by autologous stem-cell transplantation (ASCT) on patients with AITL.
  • The source of the stem cells was peripheral blood in 143 patients.
  • Forty-two patients died as a result of disease progression, and nine died as a result of regimen-related toxicity.
  • Disease status at transplantation was the major factor that impacted outcome.
  • The estimated PFS rates for patients who received their transplants in CR were 70% and 56% at 24 and 48 months, respectively; 42% and 30% for patients with chemotherapy-sensitive disease at those time points, respectively; and 23% at both time points for patients with chemotherapy-refractory disease.
  • CONCLUSION: This study shows that HDT and ASCT offers the possibility of long-term disease-free survival to patients with AITL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunoblastic Lymphadenopathy / drug therapy. Immunoblastic Lymphadenopathy / therapy. Stem Cell Transplantation
  • [MeSH-minor] Aged. Carmustine / administration & dosage. Combined Modality Therapy. Cytarabine / administration & dosage. Disease Progression. Etoposide / administration & dosage. Female. Humans. Male. Melphalan / administration & dosage. Middle Aged. Neoplasm Recurrence, Local. Proportional Hazards Models. Remission Induction. Retrospective Studies. Survival Analysis. Transplantation Conditioning. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2009 Jul 1;27(19):3262
  • (PMID = 18182664.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine
  •  go-up   go-down


48. Takamatsu Y, Suzumiya J, Utsunomiya A, Maeda K, Matsuoka H, Suzushima H, Tsukada J, Shibata K, Tamura K, Kyushu Hematology Organization for Treatment Study Group (K-HOT): THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma: a multicenter phase II study. Eur J Haematol; 2010 May;84(5):391-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma: a multicenter phase II study.
  • OBJECTIVE: The efficacy of pirarubicin (THP)-COP was previously compared with cyclophophamide + doxorubicin + vincristine + prednisolone (CHOP) in elderly patients with lymphoma.
  • The subset analysis showed that T-cell lymphoma had a significantly better response with THP-COP, whereas no such difference was observed in B-cell lymphoma.
  • The aim of this study is to confirm the efficacy of THP-COP in the treatment of T-cell lymphoma.
  • METHODS: We underwent a multicenter phase II study of THP-COP as a first-line treatment for T-cell lymphoma.
  • Seventeen patients had peripheral T-cell lymphoma (PTCL), including nine of PTCL not otherwise specified (PTCL-NOS) and eight of angioimmunoblastic T-cell lymphoma (AITL).
  • Thirty-six patients had adult T-cell leukemia/lymphoma (ATLL), including 20 of acute type and 16 of lymphoma type.
  • Febrile neutropenia was observed in 51% and grade 3 non-hematological toxicities in 2-9% of the patients.
  • CONCLUSION: The efficacy of THP-COP is equivalent to that of CHOP for the first-line therapy in T-cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Lymphoma, T-Cell / drug therapy

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20059527.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VEP-THP protocol
  •  go-up   go-down


49. Grogg KL, Attygalle AD, Macon WR, Remstein ED, Kurtin PJ, Dogan A: Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. Mod Pathol; 2006 Aug;19(8):1101-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified.
  • The germinal center T-helper cell has been proposed as the cell of origin for angioimmunoblastic T-cell lymphoma.
  • Our recent report of expression of CXCL13, a chemokine critical for germinal center formation and one of the most highly upregulated genes in the germinal center T-helper cell subset, in the majority of angioimmunoblastic T-cell lymphoma cases, provided further support for this theory.
  • To determine the specifity of this marker for angioimmunoblastic T-cell lymphoma, we evaluated CXCL13 expression in 26 nodal-based peripheral T-cell lymphomas and 14 lymph nodes showing paracortical lymphoid hyperplasia.
  • By WHO classification criteria, 20 of the lymphoma cases were considered peripheral T-cell lymphoma, unspecified, and six were reclassified as angioimmunoblastic T-cell lymphoma after immunohistochemical detection of disorganized follicular dendritic cell meshworks.
  • Combining the results of our studies, 31 of 35 angioimmunoblastic T-cell lymphoma cases (89%) showed CXCL13 expression, in contrast to two out of 20 peripheral T-cell lymphoma, unspecified cases (10%).
  • The two peripheral T-cell lymphoma, unspecified cases that were positive for CXCL13 showed a Lennert lymphoma-like histology.
  • While these cases did not meet all histologic criteria for angioimmunoblastic T-cell lymphoma, they did show an increase in EBV-positive B cells, suggesting they may be histologic variants of angioimmunoblastic T-cell lymphoma.
  • In conclusion, CXCL13 expression is a distinctive feature of angioimmunoblastic T-cell lymphoma, providing further support for the germinal center T-helper cell as the cell of origin for this neoplasm.
  • Given its specificity when compared to cases of peripheral T-cell lymphoma, unspecified as well as paracortical lymphoid hyperplasia, it may be a useful marker in the diagnosis of angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Chemokines, CXC / metabolism. Germinal Center / metabolism. Immunoblastic Lymphadenopathy / metabolism. Lymphoma, Follicular / metabolism. Lymphoma, T-Cell, Peripheral / metabolism. T-Lymphocytes, Helper-Inducer / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Chemokine CXCL13. Diagnosis, Differential. Humans. Pseudolymphoma / metabolism. Pseudolymphoma / pathology. Up-Regulation


50. Ikonomou IM, Tierens A, Troen G, Aamot HV, Heim S, Lauritzsen GF, Vålerhaugen H, Delabie J: Peripheral T-cell lymphoma with involvement of the expanded mantle zone. Virchows Arch; 2006 Jul;449(1):78-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma with involvement of the expanded mantle zone.
  • Peripheral T-cell lymphoma (PTCL) with a nodular architecture is rare.
  • Recently, two variants have been described with infiltration of the B-cell follicle, one variant that localizes to the marginal zone with a so-called perifollicular growth pattern, and a variant that localizes to the germinal center.
  • These lymphomas have a CD4+ phenotype and may express Bcl-6.
  • We have studied five similar cases of PTCL with involvement of the B-cell follicle.
  • However, our cases differ from the cases previously described by their predominant and frequently patchy involvement of the expanded mantle zone of the B-cell follicle at onset.
  • Later biopsies in three of the cases show diffuse infiltration of the lymph node, without features of angioimmunoblastic TCL (AILT).
  • Whether our cases are part of a spectrum of PTCLs that encompasses previously described variants with predominant marginal zone or germinal center infiltration or they represent a separate T-cell lymphoma type remains to be demonstrated by a study of more of such cases.
  • [MeSH-major] Lymph Nodes / pathology. Lymphoma, Mantle-Cell / pathology. Lymphoma, T-Cell, Peripheral / pathology

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2005 Mar;123(3):448-55 [15716242.001]
  • [Cites] Am J Surg Pathol. 2000 Jan;24(1):117-22 [10632495.001]
  • [Cites] J Histochem Cytochem. 1981 Apr;29(4):577-80 [6166661.001]
  • [Cites] Nat Genet. 1997 Jun;16(2):161-70 [9171827.001]
  • [Cites] Bone Marrow Transplant. 2002 May;29(9):799-801 [12040480.001]
  • [Cites] Nature. 1994 Dec 8;372(6506):556-9 [7990929.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):661-9 [10666395.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13823-8 [9811885.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):1067-71 [10702422.001]
  • [Cites] Int J Hematol. 2001 Feb;73(2):262-5 [11372742.001]
  • [Cites] Eur J Immunol. 1998 May;28(5):1604-10 [9603466.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3369-73 [12384439.001]
  • [Cites] Blood. 2002 Jan 15;99(2):627-33 [11781247.001]
  • [Cites] Lab Invest. 2001 Dec;81(12):1693-702 [11742039.001]
  • [Cites] Eur J Immunol. 1999 Nov;29(11):3729-36 [10556829.001]
  • [Cites] Am J Pathol. 1995 Jan;146(1):46-55 [7856738.001]
  • [Cites] Am J Surg Pathol. 1995 Mar;19(3):297-303 [7872427.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2640-8 [7919378.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Feb;117(1):71-9 [10700871.001]
  • [Cites] Nature. 1996 Jun 27;381(6585):751-8 [8657279.001]
  • [Cites] Am J Surg Pathol. 2001 Mar;25(3):395-400 [11224611.001]
  • [Cites] Blood. 1995 Jul 1;86(1):45-53 [7795255.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12520-4 [8618933.001]
  • [Cites] Blood. 2001 Jan 1;97(1):270-6 [11133771.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2445-50 [9310496.001]
  • [Cites] Hum Pathol. 1999 Apr;30(4):403-11 [10208461.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):643-55 [9630171.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11816-21 [9751748.001]
  • [Cites] Arch Pathol Lab Med. 1988 Feb;112(2):133-8 [3257382.001]
  • (PMID = 16633785.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins c-bcl-6
  •  go-up   go-down


51. Willenbrock K, Renné C, Gaulard P, Hansmann ML: In angioimmunoblastic T-cell lymphoma, neoplastic T cells may be a minor cell population. A molecular single-cell and immunohistochemical study. Virchows Arch; 2005 Jan;446(1):15-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In angioimmunoblastic T-cell lymphoma, neoplastic T cells may be a minor cell population. A molecular single-cell and immunohistochemical study.
  • The significance of T-cell proliferations in angioimmunoblastic lymphoma (AILD) is still enigmatic.
  • Although classified as a malignant T-cell lymphoma in the World Health Organisation lymphoma classification, some cases of AILD lack dominant T-cell clones.
  • In a previous study, based on single-cell polymerase chain reaction (PCR), we obtained similar results as studies of AILD using Southern blot or conventional PCR: some cases of AILD contained large T-cell clones, and, in other cases, T-cell clones were undetectable.
  • As in single-cell studies, only a limited number of cells could be investigated; thus, we wanted to gain more insight into the amount and distribution of tumour cells.
  • By applying triple immunofluorescent staining with antibodies directed against T-cell receptor Vbeta-family-specific epitopes, we investigated T-cell populations in AILD and their localisation in the tissue in relation to B cells (CD20) and follicular dendritic cells (CD21).
  • [MeSH-major] Immunoblastic Lymphadenopathy / immunology. Lymphoma, T-Cell / immunology. T-Lymphocytes / pathology
  • [MeSH-minor] Antigens, CD20 / analysis. Fluorescent Antibody Technique. Humans. Immunohistochemistry. Polymerase Chain Reaction. Receptors, Antigen, T-Cell, alpha-beta / analysis. Receptors, Complement 3d / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 1994;424(6):593-600 [8055152.001]
  • [Cites] Leuk Lymphoma. 2000 Aug;38(5-6):541-5 [10953975.001]
  • [Cites] N Engl J Med. 1975 Jan 2;292(1):1-8 [1078547.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):661-9 [10666395.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):1067-71 [10702422.001]
  • [Cites] Blood. 1995 May 15;85(10):2862-9 [7742548.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1851-7 [11337383.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10962-6 [7971992.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1985;406(1):105-24 [3922106.001]
  • [Cites] EMBO J. 1993 Dec 15;12(13):4955-67 [8262038.001]
  • [Cites] J Exp Med. 1996 Oct 1;184(4):1495-505 [8879220.001]
  • [Cites] Eur J Immunol. 1998 Aug;28(8):2424-31 [9710220.001]
  • [Cites] Blood. 1994 Jul 15;84(2):574-81 [8025283.001]
  • [Cites] Leukemia. 1997 Jul;11(7):1055-62 [9204991.001]
  • [Cites] Lancet. 1974 Jun 1;1(7866):1070-3 [4135245.001]
  • [Cites] Am J Pathol. 1988 Dec;133(3):549-56 [2849301.001]
  • [Cites] Am J Pathol. 1986 Mar;122(3):392-7 [3082212.001]
  • [Cites] Dtsch Med Wochenschr. 1975 May 23;100(21):1157-63 [1132324.001]
  • (PMID = 15480765.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Receptors, Complement 3d
  •  go-up   go-down


52. Genovesi-Ebert A, Lombardi M, Capochiani E, Simi U, Savoia MT, Baldini U, Digiorgio A, Carluccio M, Di Santo D, Galli M: Heart involvement in T cell lymphoma through hypereosinophilic syndrome: a common complication of a rare condition. J Cardiovasc Magn Reson; 2005;7(2):495-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heart involvement in T cell lymphoma through hypereosinophilic syndrome: a common complication of a rare condition.
  • This case describes a 42-year-old male affected by hypereosinophilic syndrome associated with angioimmunoblastic lymphoma.
  • Finally, the study investigates the association of T cell lymphoma, hypereosinophilic syndrome, and Loeffler endomyocardial disease.
  • [MeSH-major] Endomyocardial Fibrosis / diagnosis. Hypereosinophilic Syndrome / complications. Lymphoma, T-Cell / diagnosis

  • Genetic Alliance. consumer health - Hypereosinophilic syndromes.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15881534.001).
  • [ISSN] 1097-6647
  • [Journal-full-title] Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance
  • [ISO-abbreviation] J Cardiovasc Magn Reson
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


53. Zeniya M, Watanabe F, Morizane T, Shibata M, Maeyama S, Kage M, Nakanuma Y, Toda G, Study Group of Intractable Liver Diseases for Research on a Specific Disease, Health Science Research Grant, Ministry of Health, Labour, and Welfare of Japan: Diagnosing clinical subsets of autoimmune liver diseases based on a multivariable model. J Gastroenterol; 2005 Dec;40(12):1148-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosing clinical subsets of autoimmune liver diseases based on a multivariable model.
  • BACKGROUND: Diagnosing autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), primary sclerosing cholangitis, and other autoimmune liver diseases remains an imperfect process.
  • METHODS: We conducted a national survey and identified 988 cases of liver disease which did not satisfy the inclusion criteria for any liver disease of known etiology.
  • We expected these cases to include autoimmune liver disease (AILD) and its variant forms.
  • We selected 269 prototype cases for which histological re-evaluation of liver biopsy by independent expert hepatopathologists and the original diagnosis coincided.
  • We did a multiple logistic regression analysis to determine explanatory variables that would distinguish cases of AIH and PBC from those of non-AIH and non-PBC, respectively.
  • We constructed a multivariable diagnostic formula that gave AIH and PBC disease probabilities and validated it in a study of an additional 371 cases (validation group).
  • RESULTS: Based on the results of the statistical analysis, we selected three laboratory tests and four histological features as independent variables correlated to the diagnosis of both AIH and PBC.
  • For the validation group, assuming that the original diagnosis was correct, the sensitivity and specificity for AIH were 86.3% and 92.4%, respectively.
  • A detailed analysis of inconsistent cases showed that the diagnosis based on the formula had given the correct diagnosis, for either AIH or PBC, except for 5 cases (1.3%) in which disease probability was low for both.
  • CONCLUSIONS: A seven-variable formula based on three laboratory tests and four histological features gives significant information for the diagnosis of AILD.
  • [MeSH-major] Autoimmune Diseases / diagnosis. Liver Diseases / diagnosis
  • [MeSH-minor] Algorithms. Cholangitis, Sclerosing / diagnosis. Female. Hepatitis, Autoimmune / diagnosis. Humans. Liver Cirrhosis, Biliary / diagnosis. Male. Middle Aged. Models, Theoretical. Regression Analysis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Gastroenterol. 2005 Dec;40(12):1163-6 [16378184.001]
  • [Cites] Gut. 1994 Feb;35(2):260-5 [8307480.001]
  • [Cites] Dtsch Med Wochenschr. 1987 Sep 18;112(38):1454-8 [3622293.001]
  • [Cites] J Hepatol. 1999 Nov;31(5):929-38 [10580593.001]
  • [Cites] Gastroenterol Jpn. 1985 Oct;20(5):476-85 [4076730.001]
  • [Cites] Clin Liver Dis. 2002 May;6(2):349-62, vi [12122860.001]
  • [Cites] Am J Clin Pathol. 2000 Nov;114(5):705-11 [11068543.001]
  • [Cites] J Gastroenterol Hepatol. 1997 Oct;12(9-10):S256-71 [9407346.001]
  • [Cites] BMJ. 1996 Sep 7;313(7057):569-70 [8806239.001]
  • [Cites] Baillieres Best Pract Res Clin Gastroenterol. 2000 Aug;14(4):585-99 [10976016.001]
  • [Cites] BMC Gastroenterol. 2001;1:12 [11707153.001]
  • [Cites] Gastroenterology. 1994 Dec;107(6):1839-43 [7958699.001]
  • [Cites] Semin Liver Dis. 1985 Aug;5(3):241-53 [3901273.001]
  • [Cites] Curr Gastroenterol Rep. 1999 Feb-Mar;1(1):63-70 [10980929.001]
  • [Cites] Hepatology. 1998 Aug;28(2):360-5 [9695997.001]
  • [Cites] Hepatology. 2002 Feb;35(2):409-13 [11826416.001]
  • [Cites] Ann Intern Med. 1996 Oct 1;125(7):588-98 [8815758.001]
  • [Cites] Liver. 1999 Apr;19(2):122-8 [10220742.001]
  • [Cites] Dig Dis Sci. 1995 Jun;40(6):1232-42 [7781439.001]
  • [Cites] Hepatology. 2001 Oct;34(4 Pt 1):659-65 [11584360.001]
  • [Cites] Hepatology. 1993 Jul;18(1):10-5 [8100797.001]
  • [Cites] Can J Gastroenterol. 2001 Feb;15(2):107-13 [11240380.001]
  • [Cites] J Hepatol. 1997 Jun;26(6):1207-12 [9210605.001]
  • [Cites] Am J Gastroenterol. 2001 Oct;96(10):3021-7 [11693344.001]
  • [Cites] Am J Surg Pathol. 1994 Jan;18(1):91-9 [8279631.001]
  • [Cites] Hepatology. 1998 Aug;28(2):296-301 [9695990.001]
  • [Cites] Praxis (Bern 1994). 2002 Aug 21;91(34):1339-46 [12233264.001]
  • [Cites] Semin Liver Dis. 1991 Aug;11(3):256-62 [1925651.001]
  • (PMID = 16378179.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


54. Shah ZH, Harris S, Smith JL, Hodges E: Monoclonality and oligoclonality of T cell receptor beta gene in angioimmunoblastic T cell lymphoma. J Clin Pathol; 2009 Feb;62(2):177-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonality and oligoclonality of T cell receptor beta gene in angioimmunoblastic T cell lymphoma.
  • Angioimmunoblastic T cell lymphoma (AILT) is an aggressive T cell lymphoma with an incidence of approximately 1-2% of all non-Hodgkin lymphoma.
  • The detection of clonal T cell receptor (TCR) gene rearrangements helps in the diagnosis of T cell malignancies such as AILT, where morphological and immunohistological investigations are not always sufficient to reach a definitive diagnosis.
  • TCR beta (TCRB) and TCR gamma (TCRG) gene rearrangements were analysed from 17 WHO-defined cases of AILT by PCR for the presence of TCR clonality.
  • The results of this study emphasise that TCR clonality and oligoclonality is a diagnostic feature of AILT and that BV17S1 is over-represented with no other common molecular findings.
  • [MeSH-major] Immunoblastic Lymphadenopathy / genetics. Lymphoma, T-Cell / genetics. Receptors, Antigen, T-Cell, alpha-beta / genetics
  • [MeSH-minor] DNA, Neoplasm / genetics. Gene Rearrangement, beta-Chain T-Cell Antigen Receptor. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Neoplastic Stem Cells / pathology. Polymerase Chain Reaction / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18952689.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Receptors, Antigen, T-Cell, alpha-beta
  •  go-up   go-down


56. Yamazaki T, Sawada U, Kura Y, Ito T, Takeuchi J, Hatta Y, Aikawa S, Takei K, Ishizuka H, Saiki M, Uenogawa K: Treatment of high-risk peripheral T-cell lymphomas other than anaplastic large-cell lymphoma with a dose-intensified CHOP regimen followed by high-dose chemotherapy. A single institution study. Acta Haematol; 2006;116(2):90-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of high-risk peripheral T-cell lymphomas other than anaplastic large-cell lymphoma with a dose-intensified CHOP regimen followed by high-dose chemotherapy. A single institution study.
  • We investigated the efficacy of a dose-intensified double-CHOP regimen followed by high-dose chemotherapy with or without peripheral blood stem cell transplantation (PBSCT) in 11 patients with four types of peripheral T-cell lymphoma (PTCL).
  • All angioimmunoblastic T-cell lymphoma (AILT) and subcutaneous panniculitis-like T-cell lymphoma (SPTCL) patients achieved CR; 5 of 6 have remained disease free for more than 3 years.
  • The patient with hepatosplenic lymphoma did not achieve CR even after PBSCT and underwent allogenic bone marrow transplantation (allo-BMT).
  • Thus, our regimen appears to be effective for high-risk AILT and SPTCL.
  • However, allo-BMT should be considered for high-risk of PTCLu and hepatosplenic T-cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell / drug therapy


57. Chihara D, Oki Y, Ine S, Yamamoto K, Kato H, Taji H, Kagami Y, Yatabe Y, Nakamura S, Morishima Y: Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy. Leuk Lymphoma; 2009 Dec;50(12):1999-2004
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy.
  • We evaluated multiple patient characteristics for their prognostic significance in patients with peripheral T-cell lymphoma (angioimmunoblastic T-cell lymphoma [AITL; n = 31] and peripheral T-cell lymphoma, not otherwise unspecified [PTCL-NOS; n = 37]).
  • Five-year overall survival (OS) rates in AITL and PTCL-NOS were 49% and 45%, respectively (p = 0.89).
  • In patients with PTCL-NOS, low albumin, PS > or = 2, and mediastinal lymphadenopathy were independently associated with worse OS.
  • When analysis in PTCL-NOS was performed incorporating Prognostic Index for PTCLu (PIT), low albumin and mediastinal lymphadenopathy were still both prognostic for OS.
  • Three-year progression free survival (PFS) rates in AITL and PTCL-NOS were 49% and 47%, respectively (p = 0.578).
  • In patients with PTCL-NOS, PS > or = 2 and mediastinal lymphadenopathy were independently associated with shorter PFS.
  • Besides, we showed the potential prognostic importance of albumin and mediastinal lymphadenopathy in patients with PTCL-NOS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell, Peripheral / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Combined Modality Therapy. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Lymphatic Diseases / diagnosis. Male. Mediastinal Diseases / diagnosis. Middle Aged. Prednisone / administration & dosage. Prognosis. Proportional Hazards Models. Serum Albumin / analysis. Sex Factors. Transplantation, Autologous. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19860627.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Serum Albumin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


58. Ferran M, Gallardo F, Baena V, Ferrer A, Florensa L, Pujol RM: The 'deck chair sign' in specific cutaneous involvement by angioimmunoblastic T cell lymphoma. Dermatology; 2006;213(1):50-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The 'deck chair sign' in specific cutaneous involvement by angioimmunoblastic T cell lymphoma.
  • [MeSH-major] Immunoblastic Lymphadenopathy / physiopathology. Lymphoma, T-Cell / physiopathology. Skin Neoplasms / physiopathology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16778430.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Switzerland
  •  go-up   go-down


59. Hawley RC, Cankovic M, Zarbo RJ: Angioimmunoblastic T-cell lymphoma with supervening Epstein-Barr virus-associated large B-cell lymphoma. Arch Pathol Lab Med; 2006 Nov;130(11):1707-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma with supervening Epstein-Barr virus-associated large B-cell lymphoma.
  • Patients with angioimmunoblastic T-cell lymphoma can have profound immune dysfunction and immunodeficiency.
  • Epstein-Barr virus-driven B-cell lymphoid proliferation can occur in angioimmunoblastic T-cell lymphoma, as in other immunodeficiency states.
  • However, few cases of Epstein-Barr virus-positive B-cell lymphoma arising in patients with preexisting angioimmunoblastic T-cell lymphoma have been reported.
  • We report a case of angioimmunoblastic T-cell lymphoma in which diffuse large B-cell lymphoma developed 56 months after the diagnosis of angioimmunoblastic T-cell lymphoma.
  • The patient survived for 9 years after the initial diagnosis of angioimmunoblastic T-cell lymphoma, and molecular studies performed on multiple biopsy specimens during this period revealed the dynamic nature of clonal lymphoid expansion.
  • Epstein-Barr virus latent membrane protein 1 and Epstein-Barr virus-encoded RNA were detected in the diffuse large B-cell lymphoma, suggesting that Epstein-Barr virus may have played a role in the pathogenesis of the diffuse large B-cell lymphoma.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Immunoblastic Lymphadenopathy / complications. Immunoblastic Lymphadenopathy / pathology. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / virology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17076535.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / RNA, Viral; 0 / Viral Matrix Proteins
  •  go-up   go-down


60. Mourad N, Mounier N, Brière J, Raffoux E, Delmer A, Feller A, Meijer CJ, Emile JF, Bouabdallah R, Bosly A, Diebold J, Haioun C, Coiffier B, Gisselbrecht C, Gaulard P, Groupe d'Etude des Lymphomes de l'Adulte: Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood; 2008 May 1;111(9):4463-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.
  • To evaluate the prognostic significance of clinicobiologic and pathological features in angioimmunoblastic T-cell lymphoma (AITL), 157 AITL patients were retrieved from the GELA LNH87-LNH93 randomized clinical trials.
  • In multivariate analysis, only male sex (P = .004), mediastinal lymphadenopathy (P = .041), and anemia (P = .042) adversely affected overall survival.
  • In conclusion, AITL is a morphologically heterogeneous T-cell lymphoma commonly expressing CXCL13 and CD10 and carrying few prognostic factors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell / mortality. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Chemokine CXCL13 / analysis. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Immunoblastic Lymphadenopathy. Middle Aged. Neprilysin / analysis. Prednisone / therapeutic use. Prognosis. Randomized Controlled Trials as Topic. Retrospective Studies. Survival Analysis. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):218-24 [18182664.001]
  • [Cites] Nature. 2000 Jul 20;406(6793):309-14 [10917533.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):3025-30 [10944137.001]
  • [Cites] Blood. 2002 Jan 15;99(2):627-33 [11781247.001]
  • [Cites] Hematol J. 2001;2(4):279-85 [11920261.001]
  • [Cites] Hematol J. 2001;2(6):393-5 [11920279.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2472-9 [12011124.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2134-41 [12357368.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):12-20 [12455048.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):681-91 [12780782.001]
  • [Cites] Haematologica. 2003 Nov;88(11):1272-8 [14607756.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4284-9 [12920037.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2474-9 [14645001.001]
  • [Cites] J Immunol. 2004 Jul 1;173(1):68-78 [15210760.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1952-60 [15213097.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] N Engl J Med. 1975 Jan 2;292(1):1-8 [1078547.001]
  • [Cites] Cancer. 1978 Feb;41(2):578-606 [630540.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Cancer. 1983 Jul 15;52(2):318-21 [6861074.001]
  • [Cites] Cancer. 1987 Jan 15;59(2):208-12 [3802012.001]
  • [Cites] Lancet. 1988 Feb 6;1(8580):292-3 [2893097.001]
  • [Cites] Blood. 1988 Sep;72(3):1000-6 [3046680.001]
  • [Cites] Cancer. 1989 Apr 15;63(8):1625-9 [2924270.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1018-26 [2474057.001]
  • [Cites] Leukemia. 1991 Oct;5(10):892-5 [1961023.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1789-95 [1373088.001]
  • [Cites] Blood. 1993 Jul 1;82(1):241-6 [8391875.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Ann Oncol. 1995 Sep;6(7):659-64 [8664186.001]
  • [Cites] Blood. 1996 Sep 15;88(6):2354-5 [8822958.001]
  • [Cites] Oncology. 1997 May-Jun;54(3):193-8 [9143398.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2945-53 [9256139.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):601-3 [9261530.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):643-55 [9630171.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Int J Hematol. 1998 Apr;67(3):319-29 [9650454.001]
  • [Cites] Leuk Lymphoma. 1999 Feb;32(5-6):545-52 [10048427.001]
  • [Cites] Ann Oncol. 2004 Dec;15(12):1790-7 [15550584.001]
  • [Cites] N Engl J Med. 2005 Mar 24;352(12):1197-205 [15788496.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1501-2 [16079436.001]
  • [Cites] Nat Rev Immunol. 2005 Nov;5(11):853-65 [16261173.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):490-4 [16625095.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2472-9 [16636342.001]
  • [Cites] Mod Pathol. 2006 Aug;19(8):1101-7 [16680156.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1110-1 [16861359.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):787-92 [17228021.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4952-63 [17284527.001]
  • [Cites] Am J Surg Pathol. 2007 Jul;31(7):1077-88 [17592275.001]
  • [Cites] Medicine (Baltimore). 2007 Sep;86(5):282-92 [17873758.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1309-15 [10715302.001]
  • (PMID = 18292286.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.4.24.11 / Neprilysin; VB0R961HZT / Prednisone
  • [Other-IDs] NLM/ PMC2343588
  • [Investigator] Abdalsamad I; Dagger MF; Allard C; Angonin R; d'Anjou J; Audhuy B; Audouin J; Auzanneau G; Baglin AC; Bacilli C; Bastion Y; Baumelou E; Bensimon P; Berger F; Biron P; Blaise AM; Blanc M; Boman-Ferrand F; Boehn A; Boniver J; Bordes M; Bordessoule D; Bosly A; Bosq J; Bouabdallah R; Boucheron S; Bouvier J; Brice P; Brière J; Brousse N; Brousset P; Bryon PA; Caillot D; Carbillet JP; Casasnovas RO; Caulet T; Cazals D; Charlotte F; Charvillat L; Chesneau AM; Christian B; Coiffier B; Conroy T; Cordier JF; Cordonnier C; Clauvel JP; Deconinck E; Delage M; Delannoy A; Delmer A; Delos M; Delsol G; Devidas A; Diebold J; Diviné M; Dombret H; Doyen C; Duplay H; Dupriez B; Duval C; Eisenmann JC; Elbaz D; Emberger JM; Epardeau B; Fabiani B; Felman P; Fermand JP; Fermé C; Ferrand A; Ffrench M; Fievez M; Fillet G; Fonck Y; Froment N; Gabarre J; Galian P; Gasser O; Gaulard P; Gisselbrecht C; Gosselin B; Goutier C; Guy H; Guyotat D; Haioun C; Hamels J; Herbrecht R; Hopfner O; Horschowski N; Huguet F; Jacomy P; Jaubert J; Jeandel R; Kerneis Y; Knopf JP; Kuentz M; Labouyrie E; Lancien B; Laurent G; Lavergne A; Lavignac C; Leblond V; Lecomte-Houke M; Léderlin P; Lejeune F; Leger-Ravet MB; Loire R; Marcellin R; Marolleau JP; Marit G; Martin C; Marty-Double C; De Mascarel A; Méhaut S; Merlio JP; Merignargues C; Micléa JM; Michaux JL; Molina T; Monconduit M; Morel P; Morvan F; Mosnier JF; Nédellec G; Netter-Pinon C; Noel H; Nouvel C; Patey M; Peaud PY; Perie G; Peuchmaur M; Petrella T; Pignon B; Platini C; Pluot M; Pollet JP; Pujade-Lauraine E; Raphael M; Raymond-Gelle MC; Reiffers J; Reyes F; Rochet M; Rossi JF; Roucayrol AM; Rozenbaum A; Salles G; Schill H; Sebban C; Simon M; Solal-Céligny P; Straub P; Suc E; Sutton L; Symann M; Tertian G; Thiebaut S; Thyss A; Tilly H; Travade P; Trillet V; Vernant JP; Wendum D; Xerri L
  •  go-up   go-down


61. Roncador G, García Verdes-Montenegro JF, Tedoldi S, Paterson JC, Klapper W, Ballabio E, Maestre L, Pileri S, Hansmann ML, Piris MA, Mason DY, Marafioti T: Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. Haematologica; 2007 Aug;92(8):1059-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma.
  • BACKGROUND AND OBJECTIVES: In the present paper we report that SAP, an intracytoplasmic molecule that is involved in cell signaling, is an immunohistologic marker for germinal center T cells in paraffin-embedded tissue.
  • We document its expression, and also that of PD-1 (another recently described marker of germinal center T cells to which a new antibody has been raised), in normal and neoplastic lymphoid tissue to evaluate the suggestion that helper T cells within the germinal centers of human lymphoid tissue are the cell of origin of angioimmunoblastic T-cell lymphoma (AITL), and to assess the diagnostic value of these two markers.
  • DESIGN AND METHODS: Expression of SAP and PD-1 was investigated by immunohistochemistry in paraffin-embedded tissue sections and in cell lines.
  • Western blotting was performed on cell lines, and antibody specificity was confirmed by immunostaining of transfected cells.
  • RESULTS Screening on more than 500 lymphoma biopsies showed that 95% (40/42) of cases of AITL expressed at least one of these markers.
  • However, PD-1 and SAP were also found in a minority of cases of peripheral T-cell lymphoma other than AITL, in contrast to a report that the former marker is specific for AITL.
  • This observation raises the possibility that such non-angioimmunoblastic cases may be related to germinal center helper T cells.
  • They may also prove of value in the diagnosis of this disease since a negative reaction was rarely observed in this disorder.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / analysis. Antigens, CD / analysis. Antigens, Differentiation, T-Lymphocyte / analysis. Apoptosis Regulatory Proteins / analysis. Germinal Center / pathology. Immunoblastic Lymphadenopathy / pathology. Intracellular Signaling Peptides and Proteins / analysis. Lymphoma, T-Cell / pathology. Neoplasm Proteins / analysis. T-Lymphocytes / chemistry
  • [MeSH-minor] Hodgkin Disease / metabolism. Hodgkin Disease / pathology. Humans. Lymphocytes, Tumor-Infiltrating / chemistry. Lymphocytes, Tumor-Infiltrating / pathology. Lymphoma, B-Cell / chemistry. Lymphoma, B-Cell / pathology. Palatine Tonsil / pathology. Programmed Cell Death 1 Receptor. Spleen / pathology. Thymus Gland / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640856.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antigens, CD; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Apoptosis Regulatory Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor; 0 / SH2D1A protein, human
  •  go-up   go-down


62. Bourdi M, Eiras DP, Holt MP, Webster MR, Reilly TP, Welch KD, Pohl LR: Role of IL-6 in an IL-10 and IL-4 double knockout mouse model uniquely susceptible to acetaminophen-induced liver injury. Chem Res Toxicol; 2007 Feb;20(2):208-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Male C57Bl/6 wild type (WT) and mice deficient in one or more cytokines were treated with 120 mg/kg APAP.
  • IL-6 appeared to have a causal role in controlling the unique susceptibility of IL-10/4-/- mice to APAP-induced liver disease (AILD) because IL-6 neutralizing antibody reversed the high sensitivity of these mice to AILD.
  • Moreover, IL-10/4/6-/- mice were also resistant to the enhanced susceptibility to AILD and expressed relatively low levels of most proinflammatory factor genes that were elevated in the IL-10/4-/- mice.
  • In conclusion, liver homeostasis following AILD appears to be highly dependent on the activities of both IL-10 and IL-4, which together help prevent overexpression of IL-6 and other potential hepatotoxic factors.
  • [MeSH-major] Acetaminophen / toxicity. Disease Models, Animal. Drug-Induced Liver Injury / metabolism. Interleukin-10 / deficiency. Interleukin-4 / deficiency. Interleukin-6 / physiology
  • [MeSH-minor] Animals. Antibodies / pharmacology. Arginase / antagonists & inhibitors. Arginase / biosynthesis. Biomarkers / blood. Genetic Predisposition to Disease. Glutathione / drug effects. Glutathione / metabolism. Interferons / biosynthesis. Liver / drug effects. Liver / metabolism. Liver / pathology. Mice. Mice, Knockout. Nitric Oxide / biosynthesis. Nitric Oxide / blood

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17305405.001).
  • [ISSN] 0893-228X
  • [Journal-full-title] Chemical research in toxicology
  • [ISO-abbreviation] Chem. Res. Toxicol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers; 0 / Interleukin-6; 130068-27-8 / Interleukin-10; 207137-56-2 / Interleukin-4; 31C4KY9ESH / Nitric Oxide; 362O9ITL9D / Acetaminophen; 9008-11-1 / Interferons; EC 3.5.3.1 / Arginase; GAN16C9B8O / Glutathione
  •  go-up   go-down


63. Chang ST, Lu CL, Chuang SS: CD52 expression in non-mycotic T- and NK/T-cell lymphomas. Leuk Lymphoma; 2007 Jan;48(1):117-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD52 expression in non-mycotic T- and NK/T-cell lymphomas.
  • Campath-1H or alemtuzumab, a human anti-CD52, has been shown to be effective in T-cell malignancies; however, there is very limited information on CD52 expression in T-cell lymphoma (TCL).
  • Fourteen cases of angioimmunoblastic T-cell lymphoma (AITL) were excluded as there were no reliable criteria to differentiate whether the CD52-positive cells were neoplastic T-cells, which are usually small-sized, or the usually abundant, small-to-large residual/reactive B-cells in this lymphoma sub-type.
  • In the remaining 83 tumors, CD52 was expressed in 29 (35%) tumors including 8/17 (47%) NK/T-cell lymphomas, 14/35 (40%) unspecified peripheral TCLs and 4/18 (22%) anaplastic large cell lymphomas.
  • [MeSH-major] Antigens, CD / metabolism. Antigens, Neoplasm / metabolism. Glycoproteins / metabolism. Lymphoma, T-Cell / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325855.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Glycoproteins
  •  go-up   go-down


64. Grogg KL, Attygalle AD, Macon WR, Remstein ED, Kurtin PJ, Dogan A: Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells? Blood; 2005 Aug 15;106(4):1501-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells?

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):643-55 [9630171.001]
  • [Cites] Blood. 2002 Jan 15;99(2):627-33 [11781247.001]
  • [Cites] Int J Oncol. 2004 Sep;25(3):605-13 [15289861.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1952-60 [15213097.001]
  • [Cites] Lancet. 1974 Jun 1;1(7866):1070-3 [4135245.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):601-3 [9261530.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):681-91 [12780782.001]
  • [Cites] Hum Pathol. 1999 Apr;30(4):403-11 [10208461.001]
  • [Cites] Leukemia. 2005 May;19(5):873-5 [15744336.001]
  • [Cites] Nature. 2000 Jul 20;406(6793):309-14 [10917533.001]
  • [Cites] Am J Surg Pathol. 2001 Mar;25(3):395-400 [11224611.001]
  • [CommentIn] Blood. 2006 Aug 1;108(3):1110-1 [16861359.001]
  • [CommentOn] Blood. 2004 Oct 1;104(7):1952-60 [15213097.001]
  • (PMID = 16079436.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA97274
  • [Publication-type] Comment; Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / Chemokines, CXC
  • [Other-IDs] NLM/ PMC1895208
  •  go-up   go-down


65. Rodriguez-Justo M, Attygalle AD, Munson P, Roncador G, Marafioti T, Piris MA: Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres: a neoplasia with origin in the outer zone of the germinal centre? Clinicopathological and immunohistochemical study of 10 cases with follicular T-cell markers. Mod Pathol; 2009 Jun;22(6):753-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres: a neoplasia with origin in the outer zone of the germinal centre? Clinicopathological and immunohistochemical study of 10 cases with follicular T-cell markers.
  • Angioimmunoblastic T-cell lymphoma is an aggressive peripheral T-cell lymphoma whose natural history is not fully understood.
  • The accurate recognition of Angioimmunoblastic T-cell lymphoma with pattern I remains a challenge and therefore the aim of this study is to phenotypically and morphologically characterize this variant with the use of the follicular helper T-cell (T(FH)) markers PD1, CXCL-13 and ICOS.
  • Out of the 88 Angioimmunoblastic T-cell lymphoma cases reviewed, 10 showed hyperplastic follicles.
  • Molecular probe methods for the detection of T-cell and B-cell clonality, as well as in-situ hybridization probes for EBV RNA expression, were carried out to leave no question as to the establishment of the diagnosis in each case.
  • By contrast, CD10 was found to only weakly label the neoplastic T cells, with only 5-10% of the target cell population staining for this marker.
  • Clinically, 8/9 cases presented with stage IIIB/IVB and in 2/10 cases consecutive biopsies showed 'progression' from pattern I to classical Angioimmunoblastic T-cell lymphoma.
  • In conclusion we have shown that the T(FH) cells markers PD1, CXCL13 and ICOS are useful adjuncts in the diagnosis of Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres.
  • PD1 also highlighted the presence of neoplastic cells in the outer zone of lymphoid follicles, suggesting that Angioimmunoblastic T-cell lymphoma (pattern I) may originate from T(FH) cells in this region, in accordance with previous immunological studies.
  • As the majority of cases in our series presented clinically with advanced stage disease, progression from pattern I to classical Angioimmunoblastic T-cell lymphoma may represent histological evolution rather than clinical progression.
  • [MeSH-major] Germinal Center / pathology. Lymph Nodes / pathology. Lymphoma, T-Cell / pathology. T-Lymphocytes, Helper-Inducer / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / metabolism. Antigens, Differentiation, T-Lymphocyte / metabolism. Apoptosis Regulatory Proteins / metabolism. Biomarkers, Tumor / immunology. Chemokine CXCL13 / metabolism. Female. Humans. Immunohistochemistry. Inducible T-Cell Co-Stimulator Protein. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Programmed Cell Death 1 Receptor

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19329936.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers, Tumor; 0 / Chemokine CXCL13; 0 / ICOS protein, human; 0 / Inducible T-Cell Co-Stimulator Protein; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor
  •  go-up   go-down


66. Togashi M, Wakui H, Kodama K, Kameoka Y, Komatsuda A, Nimura T, Ichinohasama R, Sawada K: Angioimmunoblastic T-cell lymphoma and membranous nephropathy: a still unreported association. Clin Exp Nephrol; 2010 Jun;14(3):288-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma and membranous nephropathy: a still unreported association.
  • A 21-year-old man with lymphadenopathy and Coombs-positive hemolytic anemia had been treated with steroid maintenance therapy.
  • He developed nephrotic syndrome with size increase of lymphadenopathy.
  • Lymph node examination disclosed angioimmunoblastic T-cell lymphoma (AITL).
  • [MeSH-major] Glomerulonephritis, Membranous / complications. Immunoblastic Lymphadenopathy / complications. Lymphoma, T-Cell / diagnosis. Nephrotic Syndrome / etiology

  • Genetic Alliance. consumer health - Membranous nephropathy.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Rheum Dis. 2001 Mar;60(3):293-5 [11171697.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):681-91 [12780782.001]
  • [Cites] Ann Rheum Dis. 1986 Jun;45(6):519-22 [3729577.001]
  • [Cites] Clin Exp Nephrol. 2008 Dec;12(6):475-8 [18839061.001]
  • [Cites] Klin Wochenschr. 1981 May 15;59(10):509-16 [7241951.001]
  • [Cites] Medicine (Baltimore). 2007 Sep;86(5):282-92 [17873758.001]
  • [Cites] Blood. 2008 May 1;111(9):4463-70 [18292286.001]
  • [Cites] N Engl J Med. 1975 Jan 2;292(1):1-8 [1078547.001]
  • [Cites] Rinsho Ketsueki. 1991 Jul;32(7):796-801 [1920845.001]
  • [Cites] J Nephrol. 2007 May-Jun;20(3):268-87 [17557260.001]
  • [Cites] Med Pediatr Oncol. 1988;16(3):206-9 [3380062.001]
  • [Cites] Exp Mol Pathol. 2000 Apr;68(2):85-94 [10716912.001]
  • [Cites] Arch Intern Med. 1981 Sep;141(10):1373-4 [7271411.001]
  • [Cites] Am J Kidney Dis. 2002 Apr;39(4):706-12 [11920335.001]
  • [Cites] Clin Exp Nephrol. 2008 Dec;12(6):421-31 [19012046.001]
  • [Cites] Am J Clin Pathol. 1979 Jan;71(1):58-63 [420173.001]
  • [Cites] Am J Kidney Dis. 2006 Jul;48(1):e3-9 [16797380.001]
  • [Cites] Ann Hematol. 2004 Nov;83(11):731-2 [15309529.001]
  • [Cites] Am J Nephrol. 1993;13(1):73-7 [8322845.001]
  • [Cites] Nephron. 1985;39(3):275-6 [3974787.001]
  • [Cites] Arch Pathol Lab Med. 1995 Apr;119(4):377-80 [7726733.001]
  • [Cites] Ann Hematol. 2004 Jul;83(7):455-9 [15034757.001]
  • [Cites] Am J Med. 1986 Jan;80(1):63-70 [3510541.001]
  • [Cites] Nephrol Dial Transplant. 2004 Mar;19(3):574-9 [14767011.001]
  • [Cites] Acta Med Scand. 1982;211(4):319-20 [7102371.001]
  • [Cites] Am J Kidney Dis. 1993 Mar;21(3):251-9 [8447300.001]
  • [Cites] Lancet. 1974 Jun 1;1(7866):1070-3 [4135245.001]
  • [Cites] Am J Pathol. 1975 May;79(2):219-36 [1096633.001]
  • [Cites] Eur J Haematol. 2001 Sep;67(3):158-64 [11737248.001]
  • [Cites] Nihon Naika Gakkai Zasshi. 1988 Sep;77(9):1440-5 [3246561.001]
  • [Cites] Kidney Int. 1997 Jan;51(1):270-6 [8995742.001]
  • [Cites] Kidney Int Suppl. 1993 Jan;39:S71-5 [8468929.001]
  • [Cites] Nephrol Dial Transplant. 1998 Feb;13(2):453-4 [9509462.001]
  • [Cites] Dtsch Med Wochenschr. 1975 May 23;100(21):1157-63 [1132324.001]
  • (PMID = 20177729.001).
  • [ISSN] 1437-7799
  • [Journal-full-title] Clinical and experimental nephrology
  • [ISO-abbreviation] Clin. Exp. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


67. Munemasa S, Sakai A, Sasaki N, Okikawa Y, Mihara K, Kimura A: [Angioimmunoblastic T-cell lymphoma complicated with EBV-associated B-cell lymphoma]. Rinsho Ketsueki; 2005 Feb;46(2):127-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic T-cell lymphoma complicated with EBV-associated B-cell lymphoma].
  • The immunohistochemical and pathologic findings from the biopsy specimens led to the diagnosis of angioimmunoblastic T-cell lymphoma (AILT) with a cluster of CD20-positive cells.
  • These findings indicated a diagnosis of angioimmunoblastic T-cell lymphoma complicated with EBV-associated B-cell lymphoma, and that immunodeficiency in AILT led to an expansion of EBV infected B-cells.
  • [MeSH-major] Epstein-Barr Virus Infections. Immunoblastic Lymphadenopathy / complications. Lymphoma, B-Cell / etiology
  • [MeSH-minor] Aged. Gene Rearrangement. Humans. Immunocompromised Host. Immunoglobulin Heavy Chains / genetics. Male. Molecular Diagnostic Techniques. Receptors, Antigen, T-Cell / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447706.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


68. Krenacs L, Schaerli P, Kis G, Bagdi E: Phenotype of neoplastic cells in angioimmunoblastic T-cell lymphoma is consistent with activated follicular B helper T cells. Blood; 2006 Aug 1;108(3):1110-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotype of neoplastic cells in angioimmunoblastic T-cell lymphoma is consistent with activated follicular B helper T cells.
  • [MeSH-major] Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell / pathology. T-Lymphocytes, Helper-Inducer / pathology

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Blood. 2005 Aug 15;106(4):1501-2 [16079436.001]
  • (PMID = 16861359.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


69. Khokhar FA, Payne WD, Talwalkar SS, Jorgensen JL, Bueso-Ramos CE, Medeiros LJ, Vega F: Angioimmunoblastic T-cell lymphoma in bone marrow: a morphologic and immunophenotypic study. Hum Pathol; 2010 Jan;41(1):79-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma in bone marrow: a morphologic and immunophenotypic study.
  • Angioimmunoblastic T-cell lymphoma is known to frequently involve bone marrow.
  • However, the histologic and immunophenotypic features of angioimmunoblastic T-cell lymphoma at this site are poorly defined.
  • We assessed 27 bone marrow specimens involved by angioimmunoblastic T-cell lymphoma from 20 patients.
  • Flow cytometry immunophenotyping revealed a CD3+CD10+ T-cell population in 2 (25%) of 8 cases assessed.
  • We conclude that the recognition and classification of angioimmunoblastic T-cell lymphoma in bone marrow are made difficult by the uncommon expression of CD10 (25%), rarity of follicular dendritic cells, and lack of CXCL13 expression at this site.
  • By contrast, programed death-1 immunohistochemical staining and double labeling using antibodies specific for BCL-6 and CD3 were helpful in appreciating the follicular T-helper cell immunophenotype of angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Bone Marrow Cells / pathology. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / metabolism. Biomarkers, Tumor / metabolism. Chemokine CXCL13 / metabolism. DNA-Binding Proteins / metabolism. Female. Flow Cytometry. Humans. Immunophenotyping. Intercellular Signaling Peptides and Proteins / metabolism. Male. Middle Aged. Neprilysin / metabolism. Programmed Cell Death 1 Ligand 2 Protein. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19740519.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / DNA-Binding Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / PDCD1LG2 protein, human; 0 / Programmed Cell Death 1 Ligand 2 Protein; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


70. Choi JH, Oh YH, Park IK: A case of pure red cell aplasia associated with angioimmunoblastic T-cell lymphoma. Cancer Res Treat; 2010 Jun;42(2):115-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of pure red cell aplasia associated with angioimmunoblastic T-cell lymphoma.
  • Pure red cell aplasia is a bone marrow failure characterized by a progressive normocytic anemia and reticulocytopenia without leucopenia and thrombocytopenia.
  • It is associated with various hematologic diseases.
  • However, pure red cell aplasia with angioimmunoblastic T cell lymphoma has rarely been reported.
  • Here we describe a 43-year-old woman with pure red cell aplasia associated with angioimmunoblastic T-cell lymphoma.
  • A CT scan of the abdomen revealed marked hepatosplenomegaly and small multiple lymphadenopathies.
  • A bone marrow biopsy revealed focal infiltration of abnormal lymphoid cells and absence of red cell precursors.
  • Splenic biopsy was compatible with angioimmunoblastic T-cell lymphoma.
  • Ultimately, diagnosis of pure red cell aplasia associated with angioimmunoblastic T-cell lymphoma was made.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Haematol. 1996;96(2):68-72 [8701703.001]
  • [Cites] Am J Hematol. 1994 Jun;46(2):72-8 [8172198.001]
  • [Cites] J R Soc Med. 1983 Oct;76(10):894-5 [6631867.001]
  • [Cites] Am J Hematol. 1999 Dec;62(4):259-60 [10589086.001]
  • [Cites] Biomed Pharmacother. 2003 Oct;57(8):326-32 [14568226.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):681-91 [12780782.001]
  • [Cites] Haematologica. 1982 Nov-Dec;67(6):919-25 [6819197.001]
  • (PMID = 20622966.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2901080
  • [Keywords] NOTNLM ; Lymphoma / Pure / Red-cell aplasia / T-cell
  •  go-up   go-down


71. Bogdanos DP, Invernizzi P, Mackay IR, Vergani D: Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol; 2008 Jun 7;14(21):3374-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liver-related autoantibodies are crucial for the correct diagnosis and classification of autoimmune liver diseases (AiLD), namely autoimmune hepatitis types 1 and 2 (AIH-1 and 2), primary biliary cirrhosis (PBC), and the sclerosing cholangitis variants in adults and children.
  • AIH-2 is specified by antibody to liver kidney microsomal antigen type-1 (anti-LKM1) and anti-liver cytosol type 1 (anti-LC1).
  • SMA, ANA and anti-LKM antibodies can be present in de-novo AIH following liver transplantation.
  • PBC is specified by antimitochondrial antibodies (AMA) reacting with enzymes of the 2-oxo-acid dehydrogenase complexes (chiefly pyruvate dehydrogenase complex E2 subunit) and disease-specific ANA mainly reacting with nuclear pore gp210 and nuclear body sp100.
  • Sclerosing cholangitis presents as at least two variants, first the classical primary sclerosing cholangitis (PSC) mostly affecting adult men wherein the only (and non-specific) reactivity is an atypical perinuclear antineutrophil cytoplasmic antibody (p-ANCA), also termed perinuclear anti-neutrophil nuclear antibodies (p-ANNA) and second the childhood disease called autoimmune sclerosing cholangitis (ASC) with serological features resembling those of type 1 AIH.
  • [MeSH-major] Autoantibodies / blood. Autoantigens / immunology. Cholangitis, Sclerosing / diagnosis. Hepatitis, Autoimmune / diagnosis. Liver Cirrhosis, Biliary / diagnosis. Serologic Tests

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Immunol. 1969 May;4(5):511-25 [5787343.001]
  • [Cites] Immunology. 1969 Aug;17(2):281-93 [5804537.001]
  • [Cites] Am J Pathol. 1973 Sep;72(3):473-88 [4125700.001]
  • [Cites] Clin Exp Immunol. 1973 Nov;15(3):331-44 [4587503.001]
  • [Cites] Br Med J. 1974 Apr 13;2(5910):80-4 [4596402.001]
  • [Cites] Immunology. 1974 Mar;26(3):589-601 [4604207.001]
  • [Cites] Clin Exp Immunol. 1976 May;24(2):266-72 [945140.001]
  • [Cites] J Clin Pathol. 1976 May;29(5):403-10 [777046.001]
  • [Cites] Clin Exp Immunol. 1979 Dec;38(3):621-8 [93995.001]
  • [Cites] Clin Exp Immunol. 1983 Oct;54(1):232-8 [6352105.001]
  • [Cites] Clin Exp Immunol. 1984 Feb;55(2):347-54 [6199139.001]
  • [Cites] Lancet. 1984 Oct 27;2(8409):954-6 [6149344.001]
  • [Cites] Lancet. 1985 Feb 23;1(8426):425-9 [2857806.001]
  • [Cites] Lancet. 1987 Feb 7;1(8528):292-4 [2880112.001]
  • [Cites] J Immunol. 1987 May 15;138(10):3525-31 [3571977.001]
  • [Cites] Gastroenterol Clin Biol. 1987 Aug-Sep;11(8-9):614 [3653625.001]
  • [Cites] Hepatology. 1987 Nov-Dec;7(6):1333-9 [3679093.001]
  • [Cites] Liver. 1987 Dec;7(6):307-15 [3437792.001]
  • [Cites] Lancet. 1988 May 14;1(8594):1067-70 [2896910.001]
  • [Cites] J Exp Med. 1988 Aug 1;168(2):801-6 [2842431.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Nov;85(21):8256-60 [3186722.001]
  • [Cites] Hepatology. 2001 Mar;33(3):591-6 [11230739.001]
  • [Cites] J Hepatol. 2001 Mar;34(3):366-72 [11322196.001]
  • [Cites] Liver. 2001 Aug;21(4):225-32 [11454184.001]
  • [Cites] Hepatology. 2001 Sep;34(3):494-501 [11526534.001]
  • [Cites] Clin Exp Immunol. 2001 Oct;126(1):37-46 [11678897.001]
  • [Cites] Liver Int. 2006 Aug;26(6):633-5 [16842317.001]
  • [Cites] Clin Chim Acta. 2006 Nov;373(1-2):183-4; author reply 185 [16714006.001]
  • [Cites] Dig Liver Dis. 2006 Oct;38(10):781-2; author reply 782-3 [16870516.001]
  • [Cites] Hepatology. 2007 Jan;45(1):118-27 [17187436.001]
  • [Cites] J Clin Pathol. 2007 Jan;60(1):107-8 [17213359.001]
  • [Cites] Am J Gastroenterol. 2006 Dec;101(12):2731-6 [17227520.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Mar;22(3):454-5 [17295788.001]
  • [Cites] Hepatology. 2007 Mar;45(3):659-65 [17326160.001]
  • [Cites] PLoS Biol. 2007 Jan;5(1):e4 [17194211.001]
  • [Cites] Diabetes Res Clin Pract. 2007 Jul;77(1):155-6 [17118481.001]
  • [Cites] Am J Gastroenterol. 2007 May;102(5):1131-2 [17489791.001]
  • [Cites] Semin Liver Dis. 2007 May;27(2):129-39 [17520513.001]
  • [Cites] Lancet. 1965 Oct 30;2(7418):878-9 [4158243.001]
  • [Cites] Gastroenterology. 1966 Oct;51(4):499-505 [5332194.001]
  • [Cites] J Exp Med. 1967 Aug 1;126(2):277-90 [4165742.001]
  • [Cites] Br J Exp Pathol. 1969 Apr;50(2):200-8 [5772074.001]
  • [Cites] J Autoimmun. 2004 Jun;22(4):353-62 [15120760.001]
  • [Cites] Semin Liver Dis. 2005 Aug;25(3):239-50 [16143941.001]
  • [Cites] Semin Liver Dis. 2005 Aug;25(3):298-310 [16143945.001]
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1261-73 [16177252.001]
  • [Cites] J Clin Pathol. 2006 Mar;59(3):280-4 [16505279.001]
  • [Cites] Hepatology. 2006 May;43(5):1135-44 [16628641.001]
  • [Cites] Semin Liver Dis. 2007 May;27(2):140-51 [17520514.001]
  • [Cites] Semin Liver Dis. 2007 May;27(2):161-72 [17520516.001]
  • [Cites] Hepatology. 2007 Jun;45(6):1583; author reply 1583-4 [17538935.001]
  • [Cites] J Clin Immunol. 2007 Jul;27(4):378-87 [17514501.001]
  • [Cites] J Clin Lab Anal. 2007;21(4):227-31 [17621358.001]
  • [Cites] Ann N Y Acad Sci. 2007 Aug;1109:519-30 [17785341.001]
  • [Cites] Liver Int. 2007 Nov;27(9):1226-31 [17919234.001]
  • [Cites] Hepatology. 1988 Nov-Dec;8(6):1662-6 [3192182.001]
  • [Cites] J Clin Invest. 1989 Mar;83(3):1066-72 [2466049.001]
  • [Cites] J Clin Invest. 1990 Jun;85(6):1967-73 [2347920.001]
  • [Cites] Hepatology. 1990 Jul;12(1):127-32 [2373473.001]
  • [Cites] Gastroenterology. 1992 Oct;103(4):1290-5 [1397887.001]
  • [Cites] Hepatology. 1992 Oct;16(4):892-8 [1398495.001]
  • [Cites] Hepatology. 1993 Mar;17(3):411-7 [8444414.001]
  • [Cites] J Immunol Methods. 1993 Feb 26;159(1-2):1-16 [8445241.001]
  • [Cites] Clin Exp Immunol. 1993 May;92(2):308-16 [7683589.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8454-9 [12832623.001]
  • [Cites] J Hepatol. 2003 Nov;39(5):860-3 [14568272.001]
  • [Cites] Hepatology. 2003 Nov;38(5):1250-7 [14578864.001]
  • [Cites] Clin Liver Dis. 2003 Nov;7(4):759-77, vi [14594130.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1476-9 [14598264.001]
  • [Cites] J Hepatol. 2004 Jan;40(1):31-9 [14672611.001]
  • [Cites] Dig Liver Dis. 2003 Nov;35(11):801-5 [14674671.001]
  • [Cites] J Rheumatol. 2003 Nov;30(11):2374-81 [14677180.001]
  • [Cites] Clin Chem. 2004 Mar;50(3):682-3; author reply 683-4 [14981048.001]
  • [Cites] Int J Immunopathol Pharmacol. 2004 Jan-Apr;17(1):83-92 [15000871.001]
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):763-4; author reply 765 [15089915.001]
  • [Cites] Hepatology. 1997 Oct;26(4):1054-66 [9328334.001]
  • [Cites] Gastroenterology. 1998 Feb;114(2):324-8 [9453493.001]
  • [Cites] Lancet. 1998 Feb 7;351(9100):409-13 [9482295.001]
  • [Cites] Gut. 1998 May;42(5):721-6 [9659171.001]
  • [Cites] Hepatology. 1998 Aug;28(2):332-40 [9695994.001]
  • [Cites] Gastroenterology. 1999 Mar;116(3):643-9 [10029623.001]
  • [Cites] Ann Clin Biochem. 1999 Mar;36 ( Pt 2):189-95 [10370735.001]
  • [Cites] Experientia. 1954 Jun 15;10(6):252-3 [13183062.001]
  • [Cites] Proc Soc Exp Biol Med. 1954 Aug-Sep;86(4):789-94 [13204357.001]
  • [Cites] Lancet. 1956 Dec 29;271(6957):1323-6 [13386250.001]
  • [Cites] Hepatology. 2007 Nov;46(5):1436-42 [17657817.001]
  • [Cites] Autoimmunity. 2008 Feb;41(1):105-10 [18176872.001]
  • [Cites] Semin Liver Dis. 1997 Feb;17(1):71-8 [9089912.001]
  • [Cites] Semin Liver Dis. 1997 Feb;17(1):79-90 [9089913.001]
  • [Cites] Hepatology. 1997 May;25(5):1090-5 [9141422.001]
  • [Cites] J Hepatol. 1997 Jun;26(6):1396-402 [9210629.001]
  • [Cites] Hepatology. 1997 Sep;26(3):567-72 [9303484.001]
  • [Cites] Hepatology. 2008 Mar;47(3):1096-7; author reply 1097 [18306217.001]
  • [Cites] Proc Staff Meet Mayo Clin. 1948 Jan 21;23(2):25-8 [18921142.001]
  • [Cites] Hepatology. 1993 Jul;18(1):1-9 [8325600.001]
  • [Cites] J Hepatol. 1993 Aug;19(1):55-63 [8301043.001]
  • [Cites] J Clin Immunol. 1994 Jan;14(1):14-9 [8132733.001]
  • [Cites] Clin Exp Immunol. 1994 Jul;97(1):94-9 [8033426.001]
  • [Cites] Gastroenterology. 1995 Apr;108(4):1159-66 [7698584.001]
  • [Cites] Biochem Mol Biol Int. 1995 Mar;35(3):473-85 [7773184.001]
  • [Cites] Gut. 1995 May;36(5):749-54 [7797126.001]
  • [Cites] Gut. 1995 Sep;37(3):406-12 [7590439.001]
  • [Cites] J Immunol Methods. 1995 Dec 1;187(2):259-64 [7499885.001]
  • [Cites] Hepatology. 1996 Jul;24(1):97-103 [8707289.001]
  • [Cites] Dig Dis Sci. 1996 Sep;41(9):1733-40 [8794787.001]
  • [Cites] Hepatology. 1996 Nov;24(5):1068-73 [8903377.001]
  • [Cites] Hepatology. 1997 Jan;25(1):6-11 [8985257.001]
  • [Cites] Hepatology. 1997 Mar;25(3):541-7 [9049195.001]
  • [Cites] Semin Liver Dis. 1997 Feb;17(1):61-9 [9089911.001]
  • [Cites] J Hepatol. 1999 Oct;31(4):635-40 [10551386.001]
  • [Cites] J Hepatol. 1999 Nov;31(5):929-38 [10580593.001]
  • [Cites] Am J Gastroenterol. 2001 Dec;96(12):3447-8 [11774973.001]
  • [Cites] J Hepatol. 2002 Jan;36(1):14-21 [11804659.001]
  • [Cites] J Rheumatol. 2002 Jan;29(1):68-74 [11824974.001]
  • [Cites] Hepatology. 2002 Mar;35(3):658-64 [11870381.001]
  • [Cites] J Clin Lab Anal. 2002;16(4):194-201 [12112392.001]
  • [Cites] Gut. 2002 Aug;51(2):259-64 [12117891.001]
  • [Cites] J Clin Pathol. 2002 Dec;55(12):906-9 [12461054.001]
  • [Cites] J Immunol. 2003 Feb 1;170(3):1481-9 [12538711.001]
  • [Cites] Am J Gastroenterol. 2003 Feb;98(2):241-3 [12591035.001]
  • [Cites] Am J Gastroenterol. 2003 Feb;98(2):431-7 [12591064.001]
  • [Cites] Clin Chem. 2003 Apr;49(4):634-43 [12651817.001]
  • [Cites] J Autoimmun. 2003 May;20(3):247-54 [12753810.001]
  • [Cites] Autoimmunity. 2002 Dec;35(8):475-83 [12765472.001]
  • [Cites] Autoimmunity. 2002 Dec;35(8):485-92 [12765473.001]
  • [Cites] Autoimmunity. 2002 Dec;35(8):515-9 [12765477.001]
  • [Cites] Autoimmunity. 2002 Dec;35(8):545-50 [12765481.001]
  • [Cites] Arthritis Res Ther. 2003;5(4):192-201 [12823850.001]
  • [Cites] N Engl J Med. 1958 Jan 23;258(4):185-8 [13493762.001]
  • [Cites] Proc Soc Exp Biol Med. 1957 Dec;96(3):575-9 [13505796.001]
  • [Cites] Lancet. 1959 Jan 10;1(7063):65-9 [13621639.001]
  • [Cites] Cancer Res. 1955 Oct;15(9):598-602 [13261081.001]
  • [Cites] J Clin Invest. 1959 Nov;38:2059-72 [14402750.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Dec;2(12):1116-22 [15625657.001]
  • [Cites] Clin Infect Dis. 2005 Feb 15;40(4):508-10 [15712071.001]
  • [Cites] Hepatology. 2005 Mar;41(3):609-16 [15726652.001]
  • [Cites] Hepatology. 2005 Aug;42(2):458-65 [16025495.001]
  • [Cites] Scand J Gastroenterol. 2004 Apr;39(4):405-6; author reply 407 [15125479.001]
  • [Cites] Clin Infect Dis. 2004 May 15;38(10):1505; author reply 1505-6 [15156495.001]
  • [Cites] J Hepatol. 2004 Jul;41(1):31-7 [15246204.001]
  • [Cites] J Hepatol. 2004 Oct;41(4):677-83 [15464251.001]
  • [Cites] Scand J Gastroenterol. 2004 Oct;39(10):981-7 [15513338.001]
  • [Cites] N Engl J Med. 2000 Apr 27;342(17):1266-71 [10781624.001]
  • [Cites] Lancet. 2000 Apr 29;355(9214):1510-5 [10801173.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):310-22 [10930366.001]
  • [Cites] Dig Liver Dis. 2000 Jun-Jul;32(5):440-6 [11030191.001]
  • [Cites] Am J Gastroenterol. 2000 Nov;95(11):3238-41 [11095348.001]
  • [Cites] Gastroenterology. 2001 Jan;120(1):239-49 [11208733.001]
  • [Cites] Hepatology. 2001 Mar;33(3):544-53 [11230733.001]
  • (PMID = 18528935.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Autoantigens; 0 / Reagent Kits, Diagnostic
  • [Number-of-references] 154
  • [Other-IDs] NLM/ PMC2716592
  •  go-up   go-down


72. Vermi W, Lonardi S, Bosisio D, Uguccioni M, Danelon G, Pileri S, Fletcher C, Sozzani S, Zorzi F, Arrigoni G, Doglioni C, Ponzoni M, Facchetti F: Identification of CXCL13 as a new marker for follicular dendritic cell sarcoma. J Pathol; 2008 Nov;216(3):356-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of CXCL13 as a new marker for follicular dendritic cell sarcoma.
  • Recently, genome-wide approaches have suggested follicular CD4 T-helper cells (T(H)F) as additional CXCL13 producers in the germinal centre and the neoplastic counterpart of T(H)F (CD4+ tumour T-cells in angioimmunoblastic T-cell lymphoma) retains the capability of producing this chemokine.
  • In reactive lymph nodes and tonsils, CXCL13 protein is mainly expressed by a subset of FDCs in B-cell follicles.
  • CXCL13 is maintained during FDC transformation, since both dysplastic FDCs from 13 cases of Castleman's disease and neoplastic FDCs from ten cases of FDC-S strongly and diffusely express this chemokine.
  • FDC-S are commonly associated with a dense intratumoural inflammatory infiltrate and immunohistochemistry showed that these lymphocytes express the CXCL13 receptor CXCR5 and are mainly of mantle zone B-cell derivation (IgD+ and TCL1+).
  • In addition to the potential biological relevance of this expression, the use of reagents directed against CXCL13 can be useful to properly identify the origin of spindle cell and epithelioid neoplasms.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 18792075.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / RNA, Messenger; 0 / Receptors, CXCR5
  •  go-up   go-down


73. Lafaras C, Mandala E, Venizelos I, Valeri R, Barbetakis N, Bischiniotis T: Cardiac tamponade as primary manifestation of angioimmunoblastic T-cell lymphoma (AILT). Coexistence with malignant mesothelioma. Onkologie; 2008 Oct;31(10):546-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac tamponade as primary manifestation of angioimmunoblastic T-cell lymphoma (AILT). Coexistence with malignant mesothelioma.
  • BACKGROUND: Cardiac tamponade (CT) as the primary clinical manifestation of lymphomas is extremely rare.
  • Angioimmunoblastic T-cell lymphoma (AILT) is characterised by systemic disease usually presenting with generalised peripheral lymphadenopathy, hepatosplenomegaly, and bone marrow infiltration.
  • CASE REPORT: We report on a 59-year-old male patient with CT as initial clinical manifestation of AILT.
  • Coexistence with malignant pleural mesothelioma was additionally revealed.
  • Cytologic examination of pericardial fluid presented diffuse lymphoid cells and sporadic malignant mesothelial cells.
  • AILT diagnosis was confirmed by thoracoscopic mediastinal lymph node and bone marrow biopsy.
  • Despite the presence of pleural effusion, the diagnosis of mesothelioma was initially established by cytologic ex-amination of pericardial fluid, due to the patient's critical cardiac condition requiring prompt subxiphoid pericardiocentesis.
  • CONCLUSION: CT as primary clinical manifestation of AILT is very rare.
  • This case reflects the differences in the underlying biology of AILT and consequently the vast spectrum of its clinical presentations.
  • Coexistence of AILT with malignant pleural mesothelioma is also extremely rare.
  • [MeSH-major] Cardiac Tamponade / diagnosis. Cardiac Tamponade / etiology. Immunoblastic Lymphadenopathy / complications. Immunoblastic Lymphadenopathy / diagnosis. Lymphoma / complications. Lymphoma / diagnosis. Mesothelioma / complications. Mesothelioma / diagnosis


74. Karube K, Aoki R, Nomura Y, Yamamoto K, Shimizu K, Yoshida S, Komatani H, Sugita Y, Ohshima K: Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases. Pathol Int; 2008 Feb;58(2):89-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases.
  • Although various CD markers have been analyzed in T-cell and natural killer (NK)-cell lymphomas, the sensitivity and specificity of these phenotypic features have not been satisfactorily characterized.
  • Flow cytometry (FCM) was used to determine the phenotypic pattern of 490 T/NK-cell lymphomas with the aid of a set of surface antigens (CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD16, CD19, CD20, CD25, CD30, CD34, and CD56).
  • In data obtained from 319 patients, CD10 expression was detected in 57% of angioimmunoblastic T-cell lymphomas, CD30 in 93% of anaplastic large cell lymphomas, CD34 in 50% of lymphoblastic lymphomas, and CD56 in 100% of extranodal NK/T-cell lymphomas nasal type.
  • A total of 92% of adult T-cell leukemia/lymphomas (ATLL) had expression of CD25 and downregulation of CD7.
  • Of special interest is that 92 ATLL (50%) were CD4+CD7-CD25+ phenotype while only four peripheral T-cell lymphoma unspecified (9%) and one (9%) cutaneous T-cell lymphoma had this phenotype.
  • Phenotypic analysis using FCM was thus found to be useful for differential diagnosis of T-cell and NK-cell lymphomas.
  • [MeSH-major] Flow Cytometry / methods. Killer Cells, Natural / pathology. Lymphoma, T-Cell / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Antigens, CD / analysis. Biomarkers, Tumor / immunology. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Immunophenotyping. Lymph Nodes / immunology. Lymph Nodes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18199158.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor
  •  go-up   go-down


75. Morito N, Yoh K, Fujioka Y, Nakano T, Shimohata H, Hashimoto Y, Yamada A, Maeda A, Matsuno F, Hata H, Suzuki A, Imagawa S, Mitsuya H, Esumi H, Koyama A, Yamamoto M, Mori N, Takahashi S: Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human. Cancer Res; 2006 Jan 15;66(2):812-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human.
  • In this study, we have found that mice transgenic for c-Maf whose expression was direct to the T-cell compartment developed T-cell lymphoma.
  • Moreover, we showed that cyclin D2, integrin beta(7), and ARK5 were up-regulated in c-Maf transgenic lymphoma cells.
  • Furthermore, 60% of human T-cell lymphomas (11 of 18 cases), classified as angioimmunoblastic T-cell lymphoma, were found to express c-Maf.
  • These results suggest that c-Maf might cause a type of T-cell lymphoma in both mice and humans and that ARK5, in addition to cyclin D2 and integrin beta(7), might be downstream target genes of c-Maf leading to malignant transformation.
  • [MeSH-major] Lymphoma, T-Cell / genetics. Proto-Oncogene Proteins c-maf / biosynthesis
  • [MeSH-minor] Animals. Cell Transformation, Neoplastic. Cyclin D2. Cyclins / biosynthesis. Gene Expression Profiling. Humans. Integrin beta Chains / biosynthesis. Mice. Protein Kinases / biosynthesis. Repressor Proteins / biosynthesis. Up-Regulation

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16424013.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCND2 protein, human; 0 / Ccnd2 protein, mouse; 0 / Cyclin D2; 0 / Cyclins; 0 / Integrin beta Chains; 0 / MAF protein, human; 0 / Maf protein, mouse; 0 / Proto-Oncogene Proteins c-maf; 0 / Repressor Proteins; 0 / integrin beta7; EC 2.7.- / Protein Kinases; EC 2.7.1.- / NUAK1 protein, human
  •  go-up   go-down


76. Nelson M, Horsman DE, Weisenburger DD, Gascoyne RD, Dave BJ, Loberiza FR, Ludkovski O, Savage KJ, Armitage JO, Sanger WG: Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma. Br J Haematol; 2008 May;141(4):461-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma.
  • Cytogenetic correlations among most types of peripheral T-cell lymphoma (PTCL) have not been very informative to date.
  • This study aimed to identify recurrent chromosomal abnormalities in angioimmunoblastic T-cell lymphoma (AITL), ALK-negative anaplastic large cell lymphoma (ALK-ALCL) and peripheral T-cell lymphoma, unspecified (PTCL-US), and to evaluate their prognostic value.
  • [MeSH-major] Chromosome Aberrations. Lymphoma, T-Cell, Peripheral / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Follow-Up Studies. Humans. Immunoblastic Lymphadenopathy / genetics. Karyotyping. Lymphoma, Large-Cell, Anaplastic / genetics. Male. Middle Aged. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341637.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


77. Doty JD, Mazur JE, Judson MA: Treatment of sarcoidosis with infliximab. Chest; 2005 Mar;127(3):1064-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/OBJECTIVES: Many patients with sarcoidosis are unable to tolerate corticosteroids or alternative therapeutic agents due to side effects or have disease refractory to these agents.
  • A drug reaction developed in one patient after several months of therapy, oral candidiasis developed in one patient, and angioimmunoblastic lymphoma developed in another patient.

  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Infliximab .
  • Hazardous Substances Data Bank. PREDNISONE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15764796.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Glucocorticoids; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab; VB0R961HZT / Prednisone
  •  go-up   go-down


78. Yamane A, Awaya N, Shimizu T, Ikeda Y, Okamoto S: Angioimmunoblastic T-cell lymphoma with polyclonal proliferation of plasma cells in peripheral blood and marrow. Acta Haematol; 2007;117(2):74-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma with polyclonal proliferation of plasma cells in peripheral blood and marrow.
  • [MeSH-major] Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell / pathology. Plasma Cells / pathology

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17106190.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 130068-27-8 / Interleukin-10
  •  go-up   go-down


79. Stacchini A, Demurtas A, Aliberti S, Francia di Celle P, Godio L, Palestro G, Novero D: The usefulness of flow cytometric CD10 detection in the differential diagnosis of peripheral T-cell lymphomas. Am J Clin Pathol; 2007 Nov;128(5):854-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The usefulness of flow cytometric CD10 detection in the differential diagnosis of peripheral T-cell lymphomas.
  • We studied the histologic and multiparameter flow cytometry (MFC) features of 12 cases of angioimmunoblastic T-cell lymphoma (AITL), 13 of mature T-cell lymphoma, and 25 control cases of reactive lymphoid hyperplasia to evaluate the role of CD10 in the differential diagnosis of peripheral T-cell lymphomas (PTCLs).
  • Mature T-cell lymphoma showed a more heterogeneous altered immunophenotypic pattern, and 2 cases of PTCL, unspecified, had clear evidence of aberrant CD10 expression on T cells.
  • A small physiologic CD3+/CD4+/CD10+ T-cell population was detected by MFC in all control cases tested (range, 0.28%-4.71%), suggesting that a normal subset of peripheral CD10+ T cells exists.
  • CD10 was a highly sensitive but incompletely specific phenotypic marker for diagnosing AITL; the differential diagnosis of PTCL, unspecified, must be related with traditional histologic features.
  • [MeSH-major] Flow Cytometry / methods. Lymphoma, T-Cell, Peripheral / chemistry. Lymphoma, T-Cell, Peripheral / diagnosis. Neprilysin / analysis
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Diagnosis, Differential. Female. Humans. Immunoblastic Lymphadenopathy / diagnosis. Immunophenotyping. Lymph Nodes / pathology. Male. Middle Aged. Pseudolymphoma / diagnosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17951210.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


80. Zhou Y, Attygalle AD, Chuang SS, Diss T, Ye H, Liu H, Hamoudi RA, Munson P, Bacon CM, Dogan A, Du MQ: Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load. Br J Haematol; 2007 Jul;138(1):44-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load.
  • The clinical and histological presentations of angioimmunoblastic T-cell lymphoma (AITL) often mimic an infectious process.
  • High EBV load was also significantly associated with B-cell monoclonality.
  • Our results demonstrate an association between EBV and HHV6B infection and the histological progression of AITL, suggesting that these viruses may play a role in the pathogenesis of this lymphoma.
  • [MeSH-major] Herpesvirus 4, Human / pathogenicity. Herpesvirus 6, Human / pathogenicity. Infectious Mononucleosis / complications. Lymphoma, Large-Cell, Immunoblastic / virology. Roseolovirus Infections / complications. Tumor Virus Infections / complications
  • [MeSH-minor] Antigens, CD20 / analysis. Antigens, CD79 / analysis. Chi-Square Distribution. Disease Progression. Genes, Viral. Humans. Immunohistochemistry. Immunophenotyping. In Situ Hybridization. Neprilysin / analysis. Polymerase Chain Reaction / methods. Viral Load

  • MedlinePlus Health Information. consumer health - Infectious Mononucleosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17555446.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD79; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


81. Tajika K, Tamai H, Mizuki T, Nakayama K, Yamaguchi H, Dan K: [Epstein-Barr virus-related B-cell lymphoma of the skin which developed early after cord blood transplantation for angioimmunoblastic T-cell lymphoma]. Rinsho Ketsueki; 2010 Feb;51(2):138-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epstein-Barr virus-related B-cell lymphoma of the skin which developed early after cord blood transplantation for angioimmunoblastic T-cell lymphoma].
  • We report here a rare case of EBV-related post-transplantation lymphoproliferative disorder (PTLD) localized to the skin.
  • The patient was a 64-year-old man diagnosed with angioimmunoblastic T cell lymphoma (AITL).
  • He underwent cord blood transplantation with a reduced intensity conditioning regimen during partial remission after chemotherapy.
  • Chimerism analysis revealed that the tumor cells were derived from donor cells, which led to the diagnosis of EBV-related PTLD.
  • [MeSH-major] Fetal Blood / transplantation. Herpesvirus 4, Human. Immunoblastic Lymphadenopathy / therapy. Lymphoma, T-Cell / therapy. Lymphoproliferative Disorders / virology. Skin Diseases / virology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20379106.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


82. Khaled A, Sfia M, Fazaa B, Kourda N, Zermani R, Baccouche K, Ben Jilani S, Kamoun MR: [Chronic prurigo revealing an angioimmunoblastic T cell lymphoma]. Tunis Med; 2009 Aug;87(8):534-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chronic prurigo revealing an angioimmunoblastic T cell lymphoma].
  • [Transliterated title] Prurigo chronique révélant un lymphome T angio- immunoblastique.
  • BACKGROUND: Cutaneous manifestations in angio-immunoblastic T cell lymphoma (AITL) can be seen in almost 50% of patients.
  • Immunohistochemical study showed T cell phenotype (CD3+).
  • Molecular biological analysis of a lymph node showed a T cell clonal proliferation.
  • The diagnosis of angio-immunoblastic T cell lymphoma was made.
  • CONCLUSION: In front of chronic prurigo with general manifestations, a careful etiologic screening should be done to detect internal disorders especially malignant hemopathies.
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis. Lymphoma, T-Cell / diagnosis. Paraneoplastic Syndromes / diagnosis. Prurigo / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20180359.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


83. Tong H, Ren Y, Qian W, Xiao F, Mai W, Meng H, Jin J: Clinicopathological study on peripheral T-cell non-Hodgkin lymphoma with bone marrow involvement: a retrospective analysis from China. Int J Hematol; 2009 Oct;90(3):303-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological study on peripheral T-cell non-Hodgkin lymphoma with bone marrow involvement: a retrospective analysis from China.
  • We reviewed 173 patients with an initial diagnosis of peripheral T-cell non-Hodgkin lymphoma (PTCL) and compared the patients with bone marrow involvement (BMI) to those without to have a better understanding of the clinical characteristics, treatments, survival and prognosis of PTCLs with BMI.
  • We found that 40% (70/173) of the patients had BMI, and its frequency was 64% in angioimmunoblastic T-cell lymphoma (TCL), 46% in PTCL unspecified, 29% in anaplastic large T-cell lymphoma, 23% in extranodal NK/T-cell lymphoma and 13% in enteropathy-type TCL.
  • In the BMI group, 36% of patients had lymphoma-associated hemophagocytic syndrome (LAHS), compared with 8% of the patients without BMI (8/103, P < 0.001).
  • The estimated 1-year overall survival (OS) rates of patients with LAHS in the BMI and non-BMI groups were 5 and 49%, respectively.
  • The increased levels of lactate dehydrogenase, fasting triglycerides and beta(2)-microglobulin between the BMI and non-BMI groups were not significantly different, but ferritin increased significantly and liver dysfunction-related diseases were seen more in the BMI group.
  • The estimated 2-year OS rate of the 67 patients with BMI, who did not lose to follow-up, was 22%, compared with 38% in the non-BMI group.
  • The estimated 2-year OS rate of patients treated by CHOP regimen was 9%, compared with 51% of those with intensive chemotherapy, with a significant difference (log rank P = 0.0008).
  • The median survival time of the 14 patients subjected to chemotherapy combined with L: -asparaginase was 365 days and that of the 7 patients undergoing hemopoietic stem cell transplantation (HSCT) was 575 days.
  • We conclude that patients with PTCLs with BMI on initial diagnosis usually have hemaphagocytic syndrome and poor prognosis.
  • BMI without lymphadenopathy is a patent clinical feature in most PTCLs.
  • Patients with anemia on initial diagnosis in the BMI group usually have poor prognosis than those without.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Lymphohistiocytosis, Hemophagocytic / drug therapy. Lymphohistiocytosis, Hemophagocytic / pathology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology


84. Tsochatzis E, Vassilopoulos D, Deutsch M, Filiotou A, Tasidou A, Archimandritis AJ: Angioimmunoblastic T-cell lymphoma-associated arthritis: case report and literature review. J Clin Rheumatol; 2005 Dec;11(6):326-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma-associated arthritis: case report and literature review.
  • Angioimmunoblastic T-cell lymphoma (AITL) is a rare type of non-Hodgkin lymphoma with systemic manifestations, including fever, lymphadenopathy, rash, and rarely arthritis.
  • AITL-associated arthritis is an uncommon manifestation of angioimmunoblastic lymphoma that can mimic RA, especially when the typical systemic features of lymphoma are absent.
  • This type of arthritis should be included in the differential diagnosis of patients presenting with an inflammatory polyarthritis.
  • [MeSH-major] Arthritis / etiology. Immunoblastic Lymphadenopathy / complications. Lymphoma, T-Cell / complications
  • [MeSH-minor] Biopsy. Bone Marrow / pathology. Diagnosis, Differential. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neck

  • Genetic Alliance. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16371804.001).
  • [ISSN] 1076-1608
  • [Journal-full-title] Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
  • [ISO-abbreviation] J Clin Rheumatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Li BZ, Zhou XY, Ye HT, Yang WT, Fan YZ, Lu HF, Shi DR: [Abnormal expression of bcl-10 protein in extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue lymphoma type]. Zhonghua Bing Li Xue Za Zhi; 2007 Dec;36(12):819-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Abnormal expression of bcl-10 protein in extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue lymphoma type].
  • OBJECTIVE: To evaluate the diagnostic role of nuclear expression of bcl-10 protein in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type.
  • METHODS: One hundred and forty cases of MALT lymphoma were collected from Cancer Hospital of Fudan University (including 38 cases from stomach, 35 cases from ocular adnexa, 16 cases from intestine, 15 cases from skin, 15 cases from salivary gland, 14 cases from lung, 3 cases from thyroid and 4 cases from other sites).
  • Ten cases of reactive follicular hyperplasia of tonsil, 5 cases of reactive lymphoid hyperplasia of orbit and 143 cases of non-Hodgkin's lymphoma other than MALT lymphoma (including 20 cases of NK/T cell lymphoma, 20 cases of follicular lymphomas, 20 cases of anaplastic large cell lymphomas, 20 cases of nodal diffuse large cell B-cell lymphoma (DLBCL), 10 cases of gastric diffuse large B-cell lymphoma, 13 cases of nodal marginal zone B-cell lymphoma, 12 cases of mantle cell lymphoma, 11 cases of splenic marginal zone B-cell lymphoma, 6 cases of angioimmunoblastic T-cell lymphoma, 6 cases of peripheral T-cell lymphoma, not otherwise specified, 3 cases of small lymphocytic lymphoma, 1 case of lymphoplasmacytic lymphoma and 1 case of plasmacytoma were used as controls.
  • As for non-MALT lymphomas, 3 gastric DLBCL showed nuclear expression.
  • In some cases of lymphoma, bcl-10 was expressed in tumor cells but not in reactive lymphoid cells.
  • On the other hand, 92.1% (129/140) of MALT lymphoma were bcl-10 positive.
  • The staining was most intense in MALT lymphoma of ocular adnexa.
  • Cytoplasmic expression of bcl-10 is seen in many different kinds of non-Hodgkin's lymphoma and reactive lymphoid conditions.
  • In some cases of lymphoma, bcl-10 is expressed in tumor cells but not in reactive lymphoid cells, suggesting a possible role of abnormal bcl-10 expression in tumorgenesis.
  • Nuclear expression of bcl-10 is seen mainly in MALT lymphoma, especially when occurring in ocular adnexa and lung.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Gene Expression Regulation, Neoplastic. Lymphoma, B-Cell, Marginal Zone / genetics. Lymphoma, B-Cell, Marginal Zone / pathology
  • [MeSH-minor] Antigens, CD20 / immunology. Cell Nucleus / genetics. Cytoplasm / genetics. Humans. Lymphocytes / pathology. Palatine Tonsil / pathology. Pseudolymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18346354.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antigens, CD20; 0 / BCL10 protein, human
  •  go-up   go-down


86. Liang Q, Ye ZY, Su ZL, Lin HL, Shao CK, Lin SX, Rao HL, Mei KY, Zhao T, Liu YH, Luo DL, Zhu MG, Chen SH, Lin TY: [Clinicopathologic study of 963 cases of mature T-cell and natural killer/T-cell lymphoma with respect to 2008 WHO classification of lymphoid neoplasms]. Zhonghua Bing Li Xue Za Zhi; 2010 May;39(5):291-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of 963 cases of mature T-cell and natural killer/T-cell lymphoma with respect to 2008 WHO classification of lymphoid neoplasms].
  • OBJECTIVE: To study the clinicopathologic features of various types of mature T-cell and natural killer (NK)/T-cell lymphoma in Guangdong, China, with respect to the 2008 WHO classification of lymphoid neoplasms.
  • METHODS: Eleven hundred and thirty-seven (1137) cases of mature T-cell or NK/T-cell lymphoma diagnosed during the period from 2002 to 2006 in Guangzhou area were retrieved.
  • RESULTS: Nine hundred and sixty-three (963) cases fulfilled the diagnostic criteria of mature T-cell or NK/T-cell lymphoma and accounted for 20.1% of all cases of lymphoma encountered during the same period (963/4801).
  • A predominance of extranodal involvement was noted in 644 cases (66.9%), while 319 cases (33.1%) showed mainly nodal disease.
  • The prevalence of various lymphoma subtypes was as follows: peripheral T-cell lymphoma, unspecified (PTCL, NOS) 293 cases (30.4%), extranodal NK/T-cell lymphoma, nasal type 281 cases (29.2%), anaplastic large cell lymphoma (ALCL) 198 cases (20.6%), and angioimmunoblastic T-cell lymphoma (AILT) 46 cases (4.8%).
  • The median age of the patients was 44 years, with the peak age of PTCL, NOS, extranodal NK/T-cell lymphoma, nasal type and AILT being 55 to 64 years, 25 to 54 years and 65 to 74 years, respectively.
  • CONCLUSIONS: Extranodal lesions predominate in mature T-cell and NK/T-cell lymphomas occurring in Guangzhou area.
  • The most common subtype was PTCL, NOS, followed by extranodal NK/T-cell lymphoma, nasal type, ALCL and AILT.
  • The relatively frequent occurrence of extranodal NK/T-cell lymphoma, nasal type in Guangdong area is likely associated with the high incidence of Epstein-Barr virus infection there.
  • [MeSH-major] Lymphoma, Extranodal NK-T-Cell / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Lymphoma, T-Cell / classification. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Child, Preschool. China. Epstein-Barr Virus Infections. Female. Humans. Immunoblastic Lymphadenopathy / metabolism. Immunoblastic Lymphadenopathy / pathology. Immunoblastic Lymphadenopathy / virology. Infant. Male. Middle Aged. Protein-Tyrosine Kinases / metabolism. Receptor Protein-Tyrosine Kinases. Retrospective Studies. Sex Factors. World Health Organization. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20654150.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


87. Attygalle AD, Kyriakou C, Dupuis J, Grogg KL, Diss TC, Wotherspoon AC, Chuang SS, Cabeçadas J, Isaacson PG, Du MQ, Gaulard P, Dogan A: Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression. Am J Surg Pathol; 2007 Jul;31(7):1077-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression.
  • Angioimmunoblastic T-cell lymphoma (AITL) is an uncommon, but aggressive nodal peripheral T-cell lymphoma.
  • Eleven cases where polymerase chain reaction results for T-cell receptor-gamma gene rearrangement were directly compared showed an identical band-size in the initial and follow-up biopsies.
  • Seven cases (23%) developed EBV-associated B-cell lymphomas [5 diffuse large B-cell lymphoma (DLBCL) and 2 classic Hodgkin lymphoma].
  • In 4 cases, a dominant B-cell clone was observed in biopsies lacking evidence of DLBCL.
  • A single case was complicated by EBV-negative DLBCL, whereas another with large cell transformation had a T-cell phenotype.
  • In conclusion, AITL represents a clonal T-cell proliferation with a stable T-cell clone throughout the disease.
  • When "morphologic high-grade transformation" occurs, it is usually due to a secondary (often EBV-associated) B-cell lymphoma, rather than a T-cell neoplasm.
  • [MeSH-major] Lymph Nodes / pathology. Lymphoma, T-Cell, Peripheral / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Biopsy. Clone Cells / metabolism. Clone Cells / pathology. Disease Progression. Disease-Free Survival. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / metabolism. Epstein-Barr Virus Infections / pathology. Female. Gene Rearrangement, T-Lymphocyte. Herpesvirus 4, Human / isolation & purification. Humans. In Situ Hybridization. Male. Middle Aged. Neoplasm Staging. RNA, Viral / analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592275.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA97274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Viral
  •  go-up   go-down


88. Su XY, Xu X, Tang Y, Li GD: [Diagnosis of hematolymphoid malignancy by using effusion fluid cytology specimens: a study of 33 cases]. Zhonghua Bing Li Xue Za Zhi; 2009 Aug;38(8):542-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis of hematolymphoid malignancy by using effusion fluid cytology specimens: a study of 33 cases].
  • METHODS: The cytospin preparations/smears and cell block sections of effusion cytology specimens from 33 cases of hematolymphoid malignancy were retrospectively reviewed.
  • In selected cases, in-situ hybridization for Epstein-Barr virus-encoded RNA and immunoglobulin and T-cell receptor gene rearrangement study were carried out as indicated.
  • RESULTS: There were 33 cases of hematolymphoid malignancy, including 12 cases of T-lymphoblastic leukemia/lymphoma, 16 cases of mature B cell neoplasm (including 9 cases of diffuse large B-cell lymphoma, 2 cases of Burkitt lymphoma, 2 cases of plasmacytoma/multiple myeloma, 2 cases of B-small lymphocytic leukemia/lymphoma and 1 case of mantle cell lymphoma), 3 cases of mature T or NK-cell neoplasm (including 1 case of extranodal nasal NK/T-cell lymphoma, 1 case of angioimmunoblastic T-cell lymphoma and 1 case of T-cell prolymphocytic leukemia), 1 case of myeloid sarcoma and 1 case of mast cell sarcoma.
  • Amongst the 33 cases studied, 16 represented disease relapses, including 8 cases of diffuse large B-cell lymphoma, 2 cases of plasmacytoma/multiple myeloma, 2 cases of B-small lymphocytic leukemia/lymphoma, 1 case of T-lymphoblastic leukemia/lymphoma, 1 case of angioimmunoblastic T-cell lymphoma, 1 case of mantle cell lymphoma and 1 case of mast cell sarcoma.
  • The remaining 17 cases showed serous effusion as the primary manifestation, with the diagnosis primarily made upon cytologic examination.
  • The cytologic findings seen in all the 33 cases studied were in agreement with the corresponding histologic diagnosis.
  • CONCLUSIONS: Diagnosis of hematolymphoid malignancy by effusion fluid cytology specimens is possible, especially when coupled with the clinical history, immunophenotype, in-situ hybridization and gene rearrangement study findings.
  • This is especially so for cases with disease relapses.
  • [MeSH-major] Ascitic Fluid / pathology. Cytodiagnosis / methods. Lymphoma, Large B-Cell, Diffuse / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / pathology. Child. Female. Humans. Immunohistochemistry. Lymphoma, Extranodal NK-T-Cell / diagnosis. Lymphoma, Extranodal NK-T-Cell / metabolism. Lymphoma, Extranodal NK-T-Cell / pathology. Male. Middle Aged. Multiple Myeloma / diagnosis. Multiple Myeloma / metabolism. Multiple Myeloma / pathology. Plasmacytoma / diagnosis. Plasmacytoma / metabolism. Plasmacytoma / pathology. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021966.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


89. Maegawa RO, Hussain S, Danila DC, Teruya-Feldstein J, Maki RG, O'Connor OA: Angioimmunoblastic T-cell lymphoma with an evolving Epstein Barr virus-positive diffuse large B-cell lymphoma with unusual clinical and pathologic findings. Leuk Lymphoma; 2007 Oct;48(10):2071-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma with an evolving Epstein Barr virus-positive diffuse large B-cell lymphoma with unusual clinical and pathologic findings.
  • [MeSH-major] Herpesvirus 4, Human / metabolism. Lymphoma, B-Cell / immunology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / virology. Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / virology
  • [MeSH-minor] Aged. Antigens, CD4 / biosynthesis. Antigens, CD8 / biosynthesis. Biopsy. Cell Proliferation. Diagnosis, Differential. Female. Humans. Immune System. Lymphatic Diseases / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17917976.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Antigens, CD8
  •  go-up   go-down


90. Yamagata T, Okamoto Y, Yamagata Y, Nakanishi M, Matsunaga K, Minakata Y, Ichinose M: Angioimmunoblastic lymphadenopathy with dysproteinaemia accompanied by pleural effusion. Respirology; 2005 Jan;10(1):124-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic lymphadenopathy with dysproteinaemia accompanied by pleural effusion.
  • Angioimmunoblastic lymphadenopathy with dysproteinaemia (AILD) is a rare lymphoproliferative disorder characterized by systemic lymphadenopathy, hepatosplenomegaly, loss of body weight, fever, skin eruption, and polyclonal hypergammaglobulinaemia.
  • Two cases of AILD accompanied by pleural effusion are reported here.
  • Cytologically, atypical plasma cells, and T-cell predominant lymphocytes were also present.
  • These findings are likely to be characteristic of pleural effusions associated with AILD and may prove to be a useful marker for diagnosis.
  • [MeSH-major] Hypergammaglobulinemia / complications. Immunoblastic Lymphadenopathy / complications. Pleural Effusion / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15691251.001).
  • [ISSN] 1323-7799
  • [Journal-full-title] Respirology (Carlton, Vic.)
  • [ISO-abbreviation] Respirology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Receptors, Interleukin-2
  •  go-up   go-down


91. Dunleavy K, Wilson WH, Jaffe ES: Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications. Curr Opin Hematol; 2007 Jul;14(4):348-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications.
  • PURPOSE OF REVIEW: Angioimmunoblastic T cell lymphoma is a complex lymphoproliferative disorder.
  • While recent evidence suggests that the Epstein-Barr virus and B cell disregulation are implicated in the disease's pathogenesis, their mechanistic roles remain largely unknown.
  • The prognosis with traditional chemotherapy has been poor, but improved understanding of the disease's pathobiology has led to several promising novel therapeutic strategies.
  • RECENT FINDINGS: The recent finding of overexpression of the chemokine CXCL13 by the neoplastic cells of angioimmunoblastic T cell lymphoma suggests that it is derived from follicular helper T cells.
  • Novel therapeutic strategies including immunomodulation with agents like cyclosporine and angiogenesis inhibition with drugs such as bevacizumab are being investigated, and show early promise in this disease.
  • SUMMARY: Diseases such as angioimmunoblastic T cell lymphoma can help illuminate the biology of the normal immune system.
  • Significant progress has been made in understanding the biology of angioimmunoblastic T cell lymphoma.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / etiology. Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] Herpesvirus 4, Human. Humans. Immunoblastic Lymphadenopathy. Vascular Endothelial Growth Factor A

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17534160.001).
  • [ISSN] 1065-6251
  • [Journal-full-title] Current opinion in hematology
  • [ISO-abbreviation] Curr. Opin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 48
  •  go-up   go-down


92. Grogg KL, Morice WG, Macon WR: Spectrum of bone marrow findings in patients with angioimmunoblastic T-cell lymphoma. Br J Haematol; 2007 Jun;137(5):416-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of bone marrow findings in patients with angioimmunoblastic T-cell lymphoma.
  • Bone marrow (BM) biopsy is often performed early in the evaluation of patients with angioimmunoblastic T-cell lymphoma (AITL), and may be the first diagnostic tissue sample; yet the BM histopathology associated with this disease has not been well described.
  • Seven (54%) were involved by AITL, which was characterised by paratrabecular and interstitial polymorphous infiltrates containing cytologically atypical lymphocytes, histiocytes and eosinophils.
  • As in lymph nodes, the lymphomatous infiltrate in some BMs contained numerous small or scattered large B cells, resembling either benign lymphoid aggregates or T cell rich large B cell lymphoma, respectively.
  • When BM biopsy preceded the diagnosis of AITL, these secondary changes were misinterpreted as chronic myeloproliferative disease (n = 2), or plasma cell dyscrasia (n = 2).
  • The spectrum of BM findings in AITL patients is important to recognise for early and accurate diagnosis in this disease.
  • [MeSH-major] Bone Marrow Examination. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] B-Lymphocytes / pathology. Chemokine CXCL13. Chemokines, CXC / analysis. Diagnosis, Differential. Eosinophils / pathology. Histiocytes / pathology. Humans. Immunohistochemistry. Lymphoma, B-Cell / pathology. Neprilysin / analysis. Red-Cell Aplasia, Pure / pathology. T-Lymphocytes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488486.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 97274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / Chemokines, CXC; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


93. Nassar D, Gabillot-Carré M, Ortonne N, Belhadj K, Allanore L, Roujeau JC, Bagot M: Atypical linear IgA dermatosis revealing angioimmunoblastic T-cell lymphoma. Arch Dermatol; 2009 Mar;145(3):342-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical linear IgA dermatosis revealing angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Immunoblastic Lymphadenopathy / complications. Immunoglobulin A / analysis. Lymphoma, T-Cell, Cutaneous / complications. Skin / immunology. Skin Diseases, Vesiculobullous / immunology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19289783.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin A
  •  go-up   go-down


94. Schmitz N, Trümper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, Peter N, Loeffler M, Rosenwald A, Pfreundschuh M: Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood; 2010 Nov 4;116(18):3418-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.
  • To evaluate outcome and prognosis of patients with T-cell lymphoma we analyzed 343 patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
  • Two hundred eighty-nine patients belonged to 1 of the 4 major T-cell lymphoma subtypes: anaplastic large cell lymphoma (ALCL), anaplastic large cell lymphoma kinase (ALK)-positive (n = 78); ALCL, ALK-negative (n = 113); peripheral T-cell lymphoma, unspecified (PTCLU; n = 70); and angioimmunoblastic T-cell lymphoma (AITL; n = 28).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Female. Humans. Killer Cells, Natural / pathology. Lymphoma, Extranodal NK-T-Cell / diagnosis. Lymphoma, Extranodal NK-T-Cell / drug therapy. Lymphoma, Extranodal NK-T-Cell / pathology. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / therapeutic use. Prognosis. Treatment Outcome. Vincristine / administration & dosage. Vincristine / therapeutic use. Young Adult


95. Rodríguez-Pinilla SM, Atienza L, Murillo C, Pérez-Rodríguez A, Montes-Moreno S, Roncador G, Pérez-Seoane C, Domínguez P, Camacho FI, Piris MA: Peripheral T-cell lymphoma with follicular T-cell markers. Am J Surg Pathol; 2008 Dec;32(12):1787-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma with follicular T-cell markers.
  • INTRODUCTION: Peripheral T-cell lymphomas (PTCLs) in western countries are uncommon tumors with unfavorable prognosis.
  • They may be subclassified as anaplastic large-cell lymphomas (ALCLs), angioimmunoblastic-T-cell lymphomas (AITLs), or unspecified peripheral T-cell lymphomas (PTCLs-U).
  • The aim of this study was to establish whether other PTCL subgroups also express TFH cell markers.
  • PD-1-positive cases, which did not fulfill all the criteria for AITL, were further evaluated in whole-tissue sections for another 12 immunohistochemical markers, including the TFH cell markers CXCL13, CD10, and BCL6.
  • Clonal Ig and T-cell receptor rearrangements and Epstein-Barr virus-encoded RNA expression were also evaluated.
  • Morphologic, clinical, and follow-up data were reviewed.
  • RESULTS: Twenty-five out of 87 non-AITL cases (28.75%) showed PD-1 immunostaining.
  • All cases expressed at least 2 TFH cell markers.
  • Of the remainder, 1 was considered to be early AITL, 1 was diagnosed as ALCL-anaplastic lymphoma kinase-negative, and 4 of the other 6 PTCLs-U had morphology consistent with lymphoepithelioid (Lennert's) lymphoma.
  • CONCLUSIONS: TFH cell markers, especially PD-1, were expressed in a subset of PTCLs not classified as AITL, although most of them shared some morphologic features with AITL.
  • This suggests that the spectrum of AITL may be wider than previously thought, possibly including cases of lymphoepithelioid (Lennert's) lymphoma.
  • [MeSH-major] Antigens, CD / biosynthesis. Apoptosis Regulatory Proteins / biosynthesis. Biomarkers / analysis. Lymphoma, T-Cell, Peripheral / classification. Lymphoma, T-Cell, Peripheral / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemokine CXCL13 / biosynthesis. Female. Gene Rearrangement, T-Lymphocyte. Humans. Immunohistochemistry. In Situ Hybridization. Lymph Nodes / metabolism. Lymph Nodes / pathology. Male. Middle Aged. Neprilysin / biosynthesis. Programmed Cell Death 1 Receptor. Proto-Oncogene Proteins / biosynthesis. Repressor Proteins / biosynthesis. T-Lymphocytes, Helper-Inducer / metabolism. T-Lymphocytes, Helper-Inducer / pathology. Tissue Array Analysis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18779728.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Apoptosis Regulatory Proteins; 0 / BCOR protein, human; 0 / Biomarkers; 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor; 0 / Proto-Oncogene Proteins; 0 / Repressor Proteins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


96. Awaya N, Adachi A, Mori T, Kamata H, Nakahara J, Yokoyama K, Yamada T, Kizaki M, Sakamoto M, Ikeda Y, Okamoto S: Fulminant Epstein-Barr virus (EBV)-associated T-cell lymphoproliferative disorder with hemophagocytosis following autologous peripheral blood stem cell transplantation for relapsed angioimmunoblastic T-cell lymphoma. Leuk Res; 2006 Aug;30(8):1059-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fulminant Epstein-Barr virus (EBV)-associated T-cell lymphoproliferative disorder with hemophagocytosis following autologous peripheral blood stem cell transplantation for relapsed angioimmunoblastic T-cell lymphoma.
  • Post-transplant lymphoproliferative disorder (PTLD) is a complication that can develop after either solid-organ or hematopoietic stem cell transplantation (HSCT).
  • T-cell PTLD is a rare disorder, especially following autologous HSCT.
  • Here we report a case of T-cell PTLD which occurred after autologous peripheral blood stem cell transplantation (PBSCT) for relapsed angioimmunoblastic T-cell lymphoma (AILT).
  • Our post-mortem study confirmed the marked proliferation of EBV-infected T-cells that differed from the original AILT clone and macrophages/histiocytes were observed in the marrow, liver, lymph nodes and lungs.
  • The patient's AILT remained in complete remission.
  • To the best of our knowledge, this is the first case of fulminant EBV-associated T-cell lymphoproliferative disorder (LPD) following autologous HSCT.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Immunoblastic Lymphadenopathy / therapy. Lymphoma, T-Cell, Peripheral / therapy. Lymphoproliferative Disorders / complications. Peripheral Blood Stem Cell Transplantation / adverse effects

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16330097.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD3; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human
  •  go-up   go-down


97. Kalyan K, Basu D, Soundararaghavan J: Immunohistochemical typing of non-Hodgkin's lymphoma-comparing working formulation and WHO classification. Indian J Pathol Microbiol; 2006 Apr;49(2):203-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical typing of non-Hodgkin's lymphoma-comparing working formulation and WHO classification.
  • The recent WHO classification of non-Hodgkin's lymphoma is based on the morphology and immunohistochemical expression of the lymphoma cells and to a lesser extent, on the molecular and cytogenetic findings.
  • Fifty-three cases of non-Hodgkin's lymphoma were included in the study.
  • Of these, seven cases were primary extra nodal lymphomas.
  • Twenty two patients had peripheral blood and/or bone marrow involvement.
  • The two most common types encountered were diffuse large cell lymphoma and small lymphocytic lymphoma.
  • 38 cases (72%) showed B cell expression and 12 cases (22.5%) showed T cell expression.
  • B-cell diffuse large cell lymphoma (26%) was found to be the predominant B cell non-Hodgkin's lymphoma.
  • The commonest T-cell lymphoma was T lymphoblastic lymphoma (67%) followed by peripheral T cell angioimmunoblastic lymphoma (25%).
  • Immunohistochemistry is a useful and necessary diagnostic modality and helps subdivide prognostically different types of non-Hodgkin's lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / classification

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933715.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3
  •  go-up   go-down


98. Ortonne N, Dupuis J, Plonquet A, Martin N, Copie-Bergman C, Bagot M, Delfau-Larue MH, Gaulier A, Haioun C, Wechsler J, Gaulard P: Characterization of CXCL13+ neoplastic t cells in cutaneous lesions of angioimmunoblastic T-cell lymphoma (AITL). Am J Surg Pathol; 2007 Jul;31(7):1068-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of CXCL13+ neoplastic t cells in cutaneous lesions of angioimmunoblastic T-cell lymphoma (AITL).
  • Skin manifestations of angioimmunoblastic T-cell lymphoma (AITL) are frequent, sometimes as first manifestations of the disease.
  • In the absence of a specific marker for neoplastic cells, diagnosis of AITL in skin biopsies is often difficult.
  • A few CD10 lymphocytes were found in only 2 samples of the AITL group, the identification of which was hampered by the presence of a dermal CD10 cell population with dendritic features.
  • In another case, a diagnosis of cutaneous marginal zone B-cell lymphoma had been proposed.
  • In conclusion, this study shows that neoplastic AITL CXCL13 T cells localize in the skin and that accurate diagnosis of AITL lesions can be done in skin specimens using CXCL13 immunostaining on paraffin-embedded tissues.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Chemokines, CXC / metabolism. Lymphoma, T-Cell, Peripheral / metabolism. T-Lymphocytes / metabolism

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592274.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / Chemokines, CXC; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


99. Jaffe ES: The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program; 2009;:523-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The 2008 WHO classification of lymphomas: implications for clinical practice and translational research.
  • Recent studies have drawn attention to the biological overlap between classical Hodgkin lymphoma (CHL) and diffuse large B-cell lymphomas (DLBCL).
  • Similarly, there is a greater appreciation of the borderlands between Burkitt lymphoma and DLBCL.
  • Among the peripheral T-cell lymphomas (PTCL), more precise definitions were introduced for several entities, including anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, enteropathy-associated T-cell lymphoma, and subcutaneous panniculitis-like T-cell lymphoma.
  • Several new variants of primary cutaneous T-cell lymphomas are proposed.
  • Finally, the subclassification and categorization of the most common lymphoma subtypes, follicular lymphoma (FL) and DLBCL, were altered to enhance diagnostic accuracy and aid in clinical management.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20008237.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 74
  •  go-up   go-down


100. Oka K, Nagayama R, Yatabe Y, Iijima S, Mori N: Angioimmunoblastic T-cell lymphoma with autoimmune thrombocytopenia: a report of two cases. Pathol Res Pract; 2010 Apr 15;206(4):270-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma with autoimmune thrombocytopenia: a report of two cases.
  • We report two patients, a 68-year-old man (Case 1) and a 66-year-old man (Case 2), with polyclonal gammopathy, lymphadenopathy, thrombocytopenia, and high platelet-associated IgG (PAIgG) level.
  • We initially diagnosed them as having angioimmunoblastic lymphadenopathy with dysproteinemia (AILD).
  • From confirmation of clear cells by careful observation and detection of rearrangement bands of T cell receptors by Southern blot hybridization analysis, we finally concluded that their diagnoses were compatible with angioimmunoblastic T-cell lymphoma (AILT).
  • AILT with autoimmune thrombocytopenia (AIT) is very rare, and all the reported cases were Japanese ones.
  • [MeSH-major] Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell / pathology. Purpura, Thrombocytopenic, Idiopathic / pathology
  • [MeSH-minor] Aged. Blotting, Southern. Diagnosis, Differential. Humans. Immunohistochemistry. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19442454.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement